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Abstract
Mast cell tumours are the most common type of skin cancer in dogs, representing a signifi-
cant concern in canine health. The molecular pathogenesis is largely unknown, but breed-
predisposition for mast cell tumour development suggests the involvement of inherited
genetic risk factors in some breeds. In this study, we aimed to identify germline risk factors
associated with the development of mast cell tumours in Labrador Retrievers, a breed with
an elevated risk of mast cell tumour development. Using a methodological approach that
combined a genome-wide association study, targeted next generation sequencing, and
TaqMan genotyping, we identified a synonymous variant in the DSCAM gene on canine
chromosome 31 that is associated with mast cell tumours in Labrador Retrievers. DSCAM
encodes a cell-adhesion molecule. We showed that the variant has no effect on the DSCAM
mRNA level but is associated with a significant reduction in the level of the DSCAM protein,
suggesting that the variant affects the dynamics of DSCAM mRNA translation. Furthermore,
we showed that the variant is also associated with mast cell tumours in Golden Retrievers, a
breed that is closely related to Labrador Retrievers and that also has a predilection for mast
cell tumour development. The variant is common in both Labradors and Golden Retrievers
and consequently is likely to be a significant genetic contributor to the increased susceptibil-
ity of both breeds to develop mast cell tumours. The results presented here not only repre-
sent an important contribution to the understanding of mast cell tumour development in
dogs, as they highlight the role of cell adhesion in mast cell tumour tumourigenesis, but they
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also emphasise the potential importance of the effects of synonymous variants in complex
diseases such as cancer.
Author summary
The combination of various genetic and environmental risk factors makes the under-
standing of the molecular circuitry behind complex diseases, like cancer, a major chal-
lenge. The homogeneous nature of pedigree dog breed genomes makes these dogs ideal
for the identification of both simple disease-causing genetic variants and genetic risk fac-
tors for complex diseases. Mast cell tumours are the most common type of canine skin
cancer, and one of the most common cancers affecting dogs of most breeds. Several
breeds, including Labrador Retrievers (which represent one of the most popular dog
breeds), have an elevated risk of mast cell tumour development. Here, by using a method-
ological approach that combined different techniques, we identified a common inherited
synonymous variant, that predisposes Labrador Retrievers to mast cell tumour develop-
ment. Interestingly, we showed that this variant, despite its synonymous nature, appears
to have an effect on translation dynamics as it is associated with reduced levels of
DSCAM, a cell adhesion molecule. The results presented here reveal dysregulation of cell
adhesion to be an important factor in mast cell tumour pathogenesis, and also highlight
the important role that synonymous variants can play in complex diseases.
Introduction
Mast cell tumours (MCTs) are the most common type of skin cancer in dogs [1], and the sec-
ond most frequent form of canine malignancy in the United Kingdom [2]. Recent estimates of
the mean age of dogs diagnosed with a MCT range from 7.5 to 9 years [3–5]. The majority of
affected dogs are successfully treated by surgery and/or local radiotherapy, but around 30% of
patients require a systemic treatment, due to tumour metastasis, and have an extremely poor
prognosis [6]. Canine MCTs share many biological features with human mastocytosis [7], a
heterogeneous group of neoplastic conditions characterised by the uncontrolled proliferation
and activation of mast cells.
Mutations in the proto-oncogene, c-kit, which encodes KIT, a member of the tyrosine
kinase family of receptors, are found in 20–30% of canine MCTs and in more than 90% of
adult human mastocytoses [8–10]. In the case of human mastocytosis, most of the mutations
are single nucleotide polymorphisms (SNPs) in exon 17, which result in alterations in the
kinase domain of the receptor, with the most reported one being the V816D substitution [11].
In canine MCTs, most c-kit alterations are tandem repeats/small indels in either exons 11 and
12 (that result in alterations in the receptor’s juxtamembrane domain), or in exons 8 and 9
that encode part of the extracellular ligand-binding domain. C-kit alterations have recently
been shown to be associated with DNA copy number alterations and with increased canine
MCT malignancy [12]. They have also been explored therapeutically, and tyrosine kinase
inhibitors are now used for the treatment of canine MCTs that cannot be surgically removed,
or that are recurrent [13]. In the case of human mastocytosis, tyrosine kinase inhibitor resis-
tance is associated with the most frequent c-kit gene mutation [14]. Although the identification
of somatic c-kit mutations has contributed to the development of therapeutics, c-kit mutations
are not found in the majority of canine MCTs [15].
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Human mastocytosis has been associated with underlying germline risk factors [16, 17].
Pedigree dog-breeds display significant differences in the incidence of MCTs; German Shep-
herd Dogs, Border Collies and Cavalier King Charles Spaniels are underrepresented amongst
affected dogs, while Boxers (Odds ratio: 15.11; [18]), Golden Retrievers (Odds ratio: 6.93;[18])
and Labrador Retrievers (Odds ratio: 4.63;[18]) have an increased risk of MCT development
[2, 4, 18, 19]. This suggests the involvement of inherited genetic risk factors in the development
of MCTs in breeds which display increased susceptibility, although there is no evidence for the
occurrence of germline c-kit risk variants.
Certain characteristics of the domestic dog’s genome make it amenable to the genetic map-
ping of inherited disease-associated variants. The successive bottlenecks in the recent history
of modern dog breeds, which were derived from extensive selection for phenotypic traits, have
resulted in long regions of linkage disequilibrium (LD) within dog breeds [20]. The conse-
quent reduced level of genetic complexity facilitates within-breed positional mapping of dis-
ease-associated variants, reducing the required study population size from the thousands
needed for mapping human disease genes to hundreds [21].
Through a genome-wide association study (GWAS) and subsequent sequence capture and
fine mapping of a region containing an associated SNP marker, Arendt and co-workers identi-
fied a germline SNP that is associated with MCTs in European Golden Retrievers [22]. The
SNP is located in an exon of the Nucleotide Binding Protein (G Protein) Alpha Inhibiting
Activity Polypeptide 2 (GNAI2) gene on canine chromosome (CFA) 20, and causes alternative
exon splicing and a truncated protein [22]. In the same study, a haplotype encompassing the
HYAL4 and SPAM11 genes on CFA14 associated with MCTs in United States (US) Golden
Retrievers was also identified [22]. More recently, a GWAS identified an association between
MCTs in US Labrador Retrievers and a SNP marker on CFA36 [23], although a susceptibility
variant has yet to be identified,
In this work, we aimed to identify germline variants that predispose Labrador Retrievers to
the development of MCTs. The identification of MCT susceptibility variants in Labrador
Retrievers could not only contribute to understanding of the molecular mechanisms involved
in canine MCT development, but could also help to shed light onto human mastocytosis path-
ogenesis. With an analysis approach that combined GWAS, targeted next generation sequenc-
ing (NGS) and TaqMan genotyping, we have identified a synonymous MCT-associated
variant that is associated with significantly reduced levels of a cell adhesion molecule.
Results
Genome-wide association study (GWAS)
We conducted an initial meta-analysis of three GWAS datasets comprising a total of 105 MCT
cases and 85 controls (Sets 1, 2, and 3 in S1 Table). This analysis revealed a SNP on CFA31 that
showed a strong statistical association with MCT just below the threshold of genome-wide statisti-
cal association (P-value = 7.6 x 10−7; Bonferroni correction for multiple testing of 115,432 SNPs:
P = 4.3 x 10−7). The strongest associated SNP BICF2P951927 was at 34.7Mb (CanFam 3.1) (Fig
1A; S1 Fig). The common T allele at this locus was associated with an increased risk of MCT.
As MCT is likely to be a complex trait, we could not identify any clear shared haplotypes
amongst cases, and examination of linkage disequilibrium (LD) amongst 2,033 GWAS SNPs
on CFA31 using the pooled set of 190 dogs did not identify any other SNPs tagged by SNP
BICF2P951927 at an r2 of 0.8 or above. We therefore delineated a critical region of association for
further interrogation of the underlying sequence using a conservative empirical statistical thresh-
old of P�0.01 for SNP association results spanning SNP BICF2P951927 (Fig 1B). This resulted in
an approximate 2.9Mb region (CanFam 3.1 co-ordinates CFA31:34433688–37366557).
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Subsequent to selection of this region for resequencing, we received three additional data-
sets comprising in total a further 68 cases and 28 controls (Sets 4, 5 and 6 in S1 Table). We
therefore repeated the above meta-analysis [one individual was dropped from dataset 3 (S1
Table) as it was reported to be suffering from cancer (not a MCT)], which comprised a total of
173 cases and 112 controls. The CFA31 association increased in strength to exceed genome-
wide statistical association in this analysis (SNP BICF2P951927; P-value = 1.9 x 10−8; S2 Fig).
We also conducted a secondary meta-analysis following individual-dataset adjustment for
population stratification and the association for this SNP further increased in magnitude to P-
value = 1.9 x 10−9; (S3 Fig). This analysis revealed additional genome-wide associated loci on
Fig 1. GWAS meta-analysis of MCT in Labrador Retrievers. A. Manhattan plot of the combined analysis of 105 cases and 85
controls from three case-control sets (Sets 1–3). Analyses comprised 115,432 SNPs. B. Regional association plot highlighting the
regions surrounding the signal for MCT in Labrador Retrievers. The horizontal red line denotes the genome-wide association
threshold based on Bonferroni correction for 115,432 tests (P-value = 4.3 x 10−7). The horizontal blue line represents the empirical
statistical threshold used to delineate the critical region surrounding the top SNP (P-value<0.01). Plots were generated using
Haploview version 4.2 [74].
https://doi.org/10.1371/journal.pgen.1007967.g001
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other chromosomes. However, we have focused on the CFA31 region here as it showed the
strongest association; analysis of the additional regions will be undertaken in future studies.
Sequence capture and identification of candidate variants
The associated 2.9Mb region of CFA31 was captured from libraries prepared from germline
DNA samples from six Labrador Retrievers affected by a MCT and six unaffected dogs over
the age of 7 years, and sequenced. All the affected dogs carried two copies of the GWAS MCT-
associated BICF2P951927 allele ‘T’, and all unaffected dogs were homozygous for the alterna-
tive allele ‘C’. A total of 19,930 variants (including 4,028 that were not found in any of the unaf-
fected dogs) were identified amongst the 12 dogs. Of the variants, 126 displayed the same
segregation pattern as the GWAS MCT-associated SNP (i.e. the six cases were homozygous for
the reference allele, and the six controls were homozygous for an alternative allele). However,
all 126 variants were located within introns (that were part of a single gene, DSCAM), and
these were not considered to be strong candidate MCT susceptibility variants. Alternatively,
variants were selected for further analysis on the basis of a combination of both: (a) The poten-
tial functional consequence assessed according to the position of a variant (regardless of
whether the variant was predicted, by Variant Effect Predictor and/or SIFT, to be deleterious),
and (b) The extent to which a variant segregated between the six cases and six controls. Specifi-
cally, 23 variants (22 SNPs and one deletion; Tables 1 and 2) that fulfilled both of the following
criteria were selected for genotyping in a large case-control set:
1. Locus position: exon, including UTRs, and predicted to be deleterious or non-deleterious,
OR splice region
AND
2. Segregation: One allele is present as at least one copy in at least one case and is not present
in any of the controls [i.e. (a) Biallelelic loci: one allele can be present in both cases and con-
trols, but the second allele must be unique to the cases; (b) Multi-allele loci: multiple alleles
can be present in both cases and controls, but one allele must be unique to the cases)
Candidate MCT susceptibility variants—Association analysis in a larger
case-control set
TaqMan Genotyping Assays were designed for the 22 SNPs. The indel variant at CFA31:3466
7505 was genotyped by fluorescent end point PCR fragment analysis. The 23 candidate MCT
susceptibility loci were genotyped in 407 UK Labrador Retrievers comprising 191 MCT cases
and 216 controls (including 71 cases and 42 controls from the GWAS study) (S2 Table). The
SNP rs850787912 was excluded from the association analysis because it strongly deviated from
Hardy-Weinberg distribution (P-value = 2.2 x 10−83), indicating assay failure.
One of the 22 analysed loci (SNP rs850678541, at CFA31:34760750) demonstrated statisti-
cal association with MCT (P-value = 5.2 x 10−4; Table 3). This association was stronger than
that of the strongest associated GWAS SNP BICF2P951927 (Table 4). The SNP is associated
with MCT with an odds ratio of 1.67 (95% confidence interval 1.24–2.24), and explains 2%
(pseudo r2) of the MCT trait in this breed. The alternative ‘A’ allele is common—72% of the
genotyped dogs (including 67% of controls) carried at least one copy, and 25% of the dogs
(including 20% of controls) carried two copies (Table 4). This allele increases the risk of MCT
development by 1.66 x (ratio of heterozygote odds: reference allele homozygote odds; 95% con-
fidence interval 0.99–2.77) when present as one copy, and by 2.79 x (ratio of alternative allele
homozygote odds: reference allele homozygote odds; 95% confidence interval 1.55–5.03) when
present as two copies.
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Investigation of the biological effects of the alternative allele of SNP
rs850678541
The alternative (variant) allele of SNP rs850678541 (CFA31:34760750) represents a G>A tran-
sition (plus DNA strand) located in exon 16 of the canine DSCAM gene, which encodes a cell
adhesion molecule. It occurs in the third base of a codon (representing arginine), and, as such,
is a synonymous mutation (changing the codon from CGC to CGT). A growing body of evi-
dence indicates that, although synonymous mutations do not cause amino acid sequence
changes, they can have an effect on factors such as mRNA stability and translation kinetics,
and thus have significant biological consequences [26–30]. Consequently, we investigated if
the alternative allele of SNP rs850678541 had any effect on DSCAM mRNA and protein levels.
Table 1. CFA31 germline variants selected from resequencing data for further investigation.
dbSNP ID. CFA31 base
co-ordinate
(CanFam3.1)
Gene Gene
DNA
Strand
Variant location Variant
type
Variant consequence
(VEP)
SIFT
Predicted
Impact
rs852630575 34482267 IGSF5 Plus 3 prime UTR SNP 3 prime UTR N/A
Not
available
34482866 IGSF5 Plus 3 prime UTR SNP 3 prime UTR N/A
N/A 34667505 DSCAM Minus 3 prime UTR indel 3 prime UTR N/A
rs850678541 34760750 DSCAM Minus exon SNP Synonymous N/A
rs852645717 34760777 DSCAM Minus exon SNP Synonymous N/A
rs23691670 34962258 DSCAM Minus exon SNP Synonymous N/A
Not
available
35933663 TMPRSS2 Minus 3 prime UTR SNP 3 prime UTR N/A
rs852502899 36248583 PRDM15 Minus exon SNP Synonymous N/A
rs852865506 36295441 C2CD2 Minus exon SNP Missense tolerated
rs850678905 36309240 C2CD2 Minus splice region and intron SNP splice region and
intron
N/A
rs850787912 36488364 UMODL1 Plus exon SNP Synonymous N/A
rs852234331 36670892 TFF2 Minus 5 prime UTR SNP 5 prime UTR N/A
rs851262732 36710190 TMPRSS3 Minus exon SNP missense deleterious
rs851939503 36710860 TMPRSS3 Minus exon/intron (transcript
difference)
SNP intron + missense N/A + low
confidence
deleterious
rs851463252 36715967 TMPRSS3 Minus exon and splice region SNP Synonymous N/A
rs852977026 36716021 TMPRSS3 Minus exon SNP Synonymous N/A
rs852791601 36718391 TMPRSS3 Minus splice region and intron SNP N/A N/A
rs850730691 36729172 TMPRSS3 Minus intron [TMPRESS-202]
and exon [TMPRSS-201]
SNP splice region and
intron
N/A
rs852281859 36741129 UBASH3A Plus exon SNP Synonymous N/A
rs852901066 36889622 SLC37A1 Plus 3 prime UTR SNP 3 prime UTR N/A
rs852902530 37034944 PDE9A Plus exon SNP Missense tolerated
rs852645838 37214961 PKNOX1;
ENSCAFG00000010539;
NDUFV3
Plus;
Minus;
Plus
splice region and intron;
intron; intron
SNP splice region and
intron; intron; intron
N/A
Not
available
37278660 U2AF1; ENSCAFG00000029964 Minus;
Plus
Upstream; exon SNP upstream + missense N/A + low
confidence
deleterious
The dbSNP database [24] ID of a previously reported SNP is stated where available. The consequence of each variant was predicted using SIFT [25]. N/A = not
applicable.
https://doi.org/10.1371/journal.pgen.1007967.t001
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DNA, RNA and protein were simultaneously extracted from 17 RNAlater-preserved MCT
biopsies borne by Labrador Retrievers (representative of the three locus CFA31:34760750
genotypes; Biopsies #1–17 in Fig 2), and from normal skin biopsies from three Labrador
Retrievers (Biopsies #18–20 in Fig 2). The levels of DSCAM mRNA and protein expression
were compared between the three genotypes.
RT-qPCR assay of DSCAM mRNA expression. Three sub-optimally ‘low concentra-
tion’ MCT RNA samples were excluded availing 14 of the 17 MCT biopsy RNA samples for assay
of DSCAM expression. Each MCT RNA sample belonged to one of three genotype groups: (a)
homozygous for SNP rs850678541 reference ‘G’ allele, (b) homozygous for SNP rs850678541
alternative ‘A’ allele, and (c) heterozygous. Prior to RT-qPCR analysis, cDNAs prepared from the
14 available MCT RNAs were screened for the presence of PCR inhibitors using the SPUD assay,
since the PCR inhibitor heparin is commonly found in mast cells [31]. The mean SPUD amplicon
Cq value and Cq SD measured for each MCT cDNA are presented in S3 Table. As the SPUD
amplicon mean Cq value showed little variation across the 14 MCT cDNAs assayed (Cq
SD = 0.24) and the largest difference between the mean SPUD Cq value for any two of the three
Table 2. Genotypes of 12 resequenced Labrador Retrievers at selected CFA31 candidate MCT susceptibility loci.
dbSNP ID. CFA31 base
co-ordinate
(CanFam3.1)
Reference allele
(a)
Alternative (‘variant’) alleles
(b, c)
Genotypes
No. MCT cases No. Controls
rs852630575 34482267 G A 2 x a/a; 4 x a/b; 0 x b/b 6 x a/a; 0 x a/b; 0 x b/b
Not
available
34482866 C G 2 x a/a; 4 x a/b; 0 x b/b 6 x a/a; 0 x a/b; 0 x b/b
N/A 34667505 AACACACAC AAC, AACACAC 0 x a/a; 0 x a/b; 0 x a/c; 6 x b/b; 0 x b/c;
0 x c/c
0 x a/a; 0 x a/b; 1 x a/c; 0 x b/b; 0 x b/c;
5 x c/c
rs850678541 34760750 G A 1 x a/a; 3 x a/b; 2 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852645717 34760777 G A 2 x a/a; 4 x a/b; 0 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs23691670 34962258 G A 2 x a/a; 2 x a/b; 2 x b/b 6 x a/a; 0 x a/b; 0 x b/b
Not
available
35933663 C T 3 x a/a; 3 x a/b; 0 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852502899 36248583 G A 2 x a/a; 3 x a/b; 1 x b/b 0 x a/a; 0 x a/b; 6 x b/b
rs852865506 36295441 C T 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs850678905 36309240 A G 1 x a/a; 4 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs850787912 36488364 C T 1 x a/a; 4 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852234331 36670892 G A 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs851262732 36710190 C T 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs851939503 36710860 G A 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs851463252 36715967 A G 1 x a/a; 4 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852977026 36716021 G A 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852791601 36718391 A G 1 x a/a; 4 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs850730691 36729172 A G 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852281859 36741129 C T 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852901066 36889622 A G 2 x a/a; 3 x a/b; 1 x b/b 6 X a/a; 0 x a/b; 0 x b/b
rs852902530 37034944 A G 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
rs852645838 37214961 G A 1 x a/a; 3 x a/b; 2 x b/b 6 x a/a; 0 x a/b; 0 x b/b
Not
available
37278660 C T 2 x a/a; 3 x a/b; 1 x b/b 6 x a/a; 0 x a/b; 0 x b/b
The reference and alternative alleles shown refer to nucleotide bases in the plus DNA strand. N/A = not applicable.
https://doi.org/10.1371/journal.pgen.1007967.t002
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genotype groups was 0.21, differences in the levels of PCR inhibitors present in each MCT sample
were considered to be negligible and all 14 MCT cDNAs were used for DSCAM mRNA analysis.
RT-qPCR assay of DSCAM mRNA expression targeted a 124 bp fragment in exon 16 of the
DSCAM gene (ENSCAFG00000010139, which encodes a 7,725b transcript ENSCAFT
00000016117). The difference between the DSCAM mRNA levels (S4 Table) measured for the
three genotype groups (Fig 3) was not statistically significant (P = 0.32; Kruskal-Wallis test)
(Fig 3A). Similarly, pairwise comparisons between genotype groups indicated no statistically
significant difference in the DSCAM mRNA levels (Reference allele homozygotes v heterozy-
gotes: Mann-Whitney U test P-value = 0.15; alternative allele homozygotes v heterozygotes:
Mann-Whitney U test P-value = 0.14; reference allele homozygotes v alternative allele homo-
zygotes: Mann-Whitney U test P-value = 1.0).
Western blot assay of DSCAM protein expression. The level of DSCAM protein in 13
MCT biopsies was measured by semi-quantitative western blot (S5 Table). Four of the 17 MCT
biopsies were excluded from this analysis on the basis of their total protein staining pattern,
which indicated degradation (S4 Fig). Each MCT protein sample belonged to one of three geno-
type groups: (a) homozygous for the SNP rs850678541 reference ‘G’ allele, (b) homozygous for
Table 3. Association analysis results for selected CFA31 candidate MCT susceptibility variants.
dbSNP ID. CFA31 base
co-ordinate
(CanFam3.1)
No. MCT cases No. Controls P-value
rs852630575 34482267 189 213 0.25
Not available 34482866 184 213 0.61
N/A 34667505 172 198 0.16/0.27�
rs850678541 34760750 168 194 5.2 x 10−4
rs852645717 34760777 181 214 0.06
rs23691670 34962258 186 207 0.52
Not available 35933663 177 202 0.28
rs852502899 36248583 173 194 0.76
rs852865506 36295441 184 206 0.43
rs850678905 36309240 185 206 0.98
rs852234331 36670892 180 202 0.44
rs851262732 36710190 180 203 0.34
rs851939503 36710860 163 167 0.91
rs851463252 36715967 181 204 0.72
rs852977026 36716021 154 142 0.66
rs852791601 36718391 172 201 0.89
rs850730691 36729172 178 204 0.64
rs852281859 36741129 182 204 0.60
rs852901066 36889622 181 199 0.57
rs852902530 37034944 179 195 0.87
rs852645838 37214961 174 196 0.80
Not available 37278660 120 168 0.49
Detailed is the number of cases and controls genotyped for each indicated variant, and the P-value obtained by testing for association using logistic regression and log
likelihood ratio test. Bonferroni correction for testing: P = 2.3 x 10−3.
�The test for association between the indel at CFA31: 34667505 and MCT was done for both genotypes/alleles using Fisher’s exact test, due to its multiallelic nature. The
numbers of MCT and control dogs genotyped in each assay varied due to DNA sample availability and variable assay performance.
https://doi.org/10.1371/journal.pgen.1007967.t003
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the SNP rs850678541 alternative ‘A’ allele, and (c) heterozygous. A substantial degree of vari-
ability in the DSCAM protein level was observed between biopsies borne by dogs that were het-
erozygous for SNP rs850678541 (Fig 4), but the difference between the DSCAM protein levels
measured for the three genotype groups was not statistically significant (P = 0.09; Kruskal-Wal-
lis test) (Fig 4B). Differences between the DSCAM protein levels of the homozygous reference
allele group and the heterozygote group (Mann-Whitney U test P-value = 1.0), and between the
homozygous alternative allele group and heterozygotes (Mann-Whitney U test P-value = 0.14)
were not statistically significant. However, the difference between the DSCAM protein expres-
sion levels of the reference allele homozygotes and alternative allele homozygotes was statisti-
cally significant (Mann-Whitney U test P-value = 0.04; Fig 4B). The mean level of DSCAM
protein in the alternative allele homozygous MCT biopsies was approximately ten times lower
than that in the reference allele homozygotes (Fig 4C). The same result was obtained regardless
of whether normalisation for variable protein loading was performed using total detected pro-
tein measured by Ponceau (Fig 4), or by Stain-Free technology (S5 Fig). A similar large-fold dif-
ference between the levels of DSCAM protein expression detected for reference allele and
alternative allele homozygotes was observed for three normal skin biopsies analysed (Fig 5).
Evaluation of the possibility that a variant at a locus in LD with SNP
rs850678541 could cause alternative splicing resulting in the ten-fold
reduction in DSCAM protein expression observed in SNP rs850678541
alternative allele homozygotes
As SNP rs850678541 is a synonymous variant, we investigated the possibility that it was not a
causal variant, but that it tagged another DSCAM gene variant that actually caused the
observed protein level effect. The variants identified by targeted resequencing of the associated
2.9Mb CFA31 region in 12 Labrador Retrievers included 2,045 at loci in the DSCAM gene. In addi-
tion to SNP rs850678541, of the remaining 2,044 DSCAM gene variants, 13 were located in exons
(five synonymous variants and eight in the 3’-UTR), 1975 were located in introns (including one
within a ‘splice region’), and 56 were upstream of the DSCAM gene. Consequently, we screened
for LD between SNP rs850678541 and each of the remaining 2,044 loci (1,950 biallelic and 94
Table 4. Genotypes of the strongest associated GWAS SNP and SNP rs850678541 in Labrador Retrievers.
Top GWAS SNP BICF2P951927 and SNP rs850678541 genotypes of LR GWAS set
BICF2P951927 No. Cases No. Controls Odds ratio
(95% CI)
P-value Model fit
(pseudo r2)
C/C 1 3 1.98
(0.90–4.36)
0.08
C/T 21 14 0.03
T/T 29 12
rs850678541 3.00
(1.45–6.18)
1.4 x 10−3
G/G 8 12 0.10
G/A 24 14
A/A 19 3
SNP rs850678541 genotypes of an extended LR case-control set
G/G 34 65 1.67
(1.24–2.24)
5.2 x 10−4
G/A 80 92 0.02
A/A 54 37
CI: confidence interval. The P-values presented were obtained by logistic regression and log likelihood ratio tests. The Labrador Retriever (LR) GWAS subset given in
this table contains only dogs for which both BICF2P951927 and rs850678541 genotypes were available. N/A = not applicable.
https://doi.org/10.1371/journal.pgen.1007967.t004
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Fig 2. SNP rs850678541 genotyping of Labrador Retriever tissue biopsies. A. Allelic discrimination plot, generated
by the TaqMan Genotyper Software, showing the distribution of the 20 biopsies analysed. Reference allele: G, and
alternative allele: A. The SNP rs850678541 genotypes are represented by: blue spheres—Alternative (variant) ‘A’ allele
homozygote; red spheres—Reference ‘G’ allele homozygote; green spheres—G/A heterozygote. B. Table showing the
status and SNP rs850678541 genotype of each biopsy.
https://doi.org/10.1371/journal.pgen.1007967.g002
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Fig 3. DSCAM mRNA levels in MCTs from Labrador Retrievers with different SNP rs850678541 genotypes. A.
Bar charts showing the DSCAM mRNA level (anti-log of the CNRQ—Calibrated Normalised Relative Quantity—
values) of the indicated biopsies, grouped by their SNP rs850678541 genotype. The differences between the groups (as
assessed by Kruskal-Wallis and Mann-Whitney U tests, respectively) were not statistically significant. B. Bar charts
showing the mean DSCAM mRNA level (anti-log of the CNRQ values) for each genotype group. Error bars represent
standard deviations. The SNP rs850678541 genotypes are represented by: ALT/ALT—Alternative (variant) ‘A’ allele
homozygote; REF/REF—Reference ‘G’ allele homozygote; REF/ALT—GA heterozygote.
https://doi.org/10.1371/journal.pgen.1007967.g003
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Fig 4. DSCAM protein levels in MCTs from Labrador Retrievers with different SNP rs850678541 genotypes. A.
DSCAM western blot prepared using protein samples extracted from the indicated MCT biopsies. Ponceau S total
protein staining was used for normalisation to adjust for variation in protein loading. Sample number colours indicate
the SNP rs850678541 genotype: Red = Alt/Alt [Alternative (variant) ‘A’ allele homozygote]; Green = Ref/Alt [GA
heterozygote]; Blue = Ref/Ref [Reference ‘G’ allele homozygote]. B. Bar charts showing the DSCAM protein levels of
the indicated biopsies, grouped by their SNP rs850678541 genotype, as quantified by the Image Lab software (using
Ponceau S-measured total protein quantity as the normaliser, and ‘Sample 6’ as the inter-membrane calibrator).
�Mann-Whitney two-tailed U test P = 0.04. C. Bar charts showing the mean DSCAM protein level of each SNP
rs850678541 genotype group. Error bars represent standard deviations.
https://doi.org/10.1371/journal.pgen.1007967.g004
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Fig 5. DSCAM protein levels in normal skin biopsies from Labrador Retrievers with different SNP rs850678541
genotypes: A. DSCAM protein levels in normal skin biopsies from Labrador Retrievers with different SNP
rs850678541 genotypes: A. DSCAM Western blot prepared using protein samples extracted from the indicated skin
biopsies (Fig 2B IDs: 18, 19, 20). Ponceau S total protein staining was used for normalisation to adjust for variation in
protein loading. Sample number colours indicate the SNP rs850678541 genotype: Red = Alt/Alt [Alternative (variant)
‘A’ allele homozygote]; Blue = Ref/Ref [Reference ‘G’ allele homozygote]. B. Histogram showing the DSCAM protein
levels of the indicated biopsies, as quantified by the Image Lab software (using Ponceau S-measured total protein
quantity as the normaliser, and ‘Sample 6’ as the inter-membrane calibrator).
https://doi.org/10.1371/journal.pgen.1007967.g005
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multiallelic). Twenty-two intronic DSCAM loci (comprising 13 SNPs and nine indels) were found
to be in LD with SNP rs850678541 at an r2 of 0.8 (S6 Table). Intronic variants can disrupt splicing
enhancer sites or branch points, and can also activate cryptic splicing sites [32] that compete with
the canonical sites, leading to the generation of alternative splicing products [33]. The antibody
employed in Western blot analysis recognises an epitope that is translated from a sequence located
in exon 23 of the DSCAM gene. Consequently, an intronic mutation that generates an alternative
mRNA transcript lacking exon 23 would not necessarily be detectable by RT-qPCR assay of
DSCAM exon 16 expression, but could lead to a reduction in the level of the 196kDa protein
encoded by the 30 exon 1,7725b DSCAM mRNA transcript (ENSCAFT00000016117), such as that
observed in the MCT and normal skin biopsies homozygous for the SNP rs850678541 alternative
‘A’ allele (Figs 4 and 5). The 22 intronic variants were screened for those that could potentially
affect mRNA splicing using the Human Splicing Finder web tool [34]. This analysis identified
three variants that could potentially lead to the generation of new splicing products: (1) a variant
(at CFA31:34767321; biallelic locus ‘16’ in S6 Table) in the intron between exons 14 and 15 that
could disrupt the splicing branch point, and generate a splicing product that would include 73
additional nucleotides from the intron; (2) a variant (at CFA31:34761118; biallelic locus ‘8’ in S6
Table) in the intron between exons 15 and 16 that could activate a cryptic intronic donor splice
site that (if used instead of the canonical site) would generate a splicing product including 5,980
nucleotides from the intron; and (3) a variant (at CFA31:34760052; biallelic locus ‘18’ in S6 Table)
in the intron between exons 16 and 17 that could also activate a cryptic intronic donor splice site
that (if used) would generate a splicing product with an additional 644 nucleotides from the intron.
End point PCR assays were performed to investigate if any of the three predicted alternative splice
variants were present in MCT biopsies borne by dogs homozygous for the alternative allele ‘A’ of
SNP rs850678541, on the presumption that dogs homozygous for this allele would also be homozy-
gous for the variants at the three intronic loci shown to be in LD with SNP rs850678541. The possi-
ble effect of the variant located in the intron between exons 14 and 15 was investigated using an
assay (E14-15 Assay) that targets an amplicon spanning the end of exon 14 and the beginning of
exon 15, whilst an assay (E15-17 Assay) targeting an amplicon spanning the end of exon 15, exon
16, and the beginning of exon 17 was employed to assess the possible effects of the variants located
in the introns between exons 15 and 16, and between exons 16 and 17, respectively. End point
PCR assay of MCT cDNAs prepared from two SNP rs850678541 reference ‘G’ allele homozygotes
and two SNP rs850678541 alternative allele ‘A’ homozygotes showed no differences between the
exonic fragments amplified (Fig 6). For both the E14-15 and E15-17 Assays only the expected
exonic mRNA fragment was amplified irrespective of SNP rs850678541 genotype (Fig 6). These
results indicate that the variants at the three intronic DSCAM loci in LD with SNP rs850678541
are not likely to cause the ten-fold reduction in DSCAM protein expression observed in MCTs
and normal skin tissues that are homozygous for SNP rs850678541 alternative allele ‘A’.
Is the SNP rs850678541 genotype associated with the age of MCT
development and MCT metastasis?
We investigated if the SNP rs850678541 genotype was associated with a difference in the mean
age at which a Labrador Retriever developed a MCT. Labrador Retrievers which were homozy-
gous for the reference ‘G’ allele had a later mean age of onset (8.59 ± 2.75 years; n = 54) than
heterozygotes (7.81 ± 2.74 years; n = 69) and dogs homozygous for the alternative ‘A’ allele
(7.82 ± 2.92 years; n = 25). However, the differences between the three genotypes (Kruskal-
Wallis test P-value = 0.52), and between pairs of genotypes (e.g. reference allele homozygotes v
alternative allele homozygotes: Mann-Whitney U test P-value = 0.37) were not statistically sig-
nificant. As the SNP rs850678541 alternative allele is associated with a significant reduction in
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the protein level expression of a cell adhesion molecule, we also undertook a preliminary inves-
tigation of whether it is also associated with MCT metastasis in Labrador Retrievers. The SNP
was genotyped in five Labrador Retrievers that died due to MCT metastatic disease (as con-
firmed by abdominal/thoracic imaging and lymph node histopathological examination) and
Fig 6. Assay forDSCAM alternative splicing: A. PCR amplicons derived from 7,725b DSCAM transcript ENSCAFT00000016117 expected to be amplified
by the E14-15 and E-15-17 Assays. The DSCAM exonic sequences illustrated are minus DNA strand sequences. B. Gel Image showing the PCR products
obtained by running the indicated PCR assays on MCT cDNAs. The sample numbers represent the IDs. of the MCT biopsies from which RNA was isolated.
Sample number colours indicate the SNP rs850678541 genotype: Red = Alt/Alt [Alternative (variant) ‘A’ allele homozygote]; Blue = Ref/Ref [Reference ‘G’
allele homozygote].
https://doi.org/10.1371/journal.pgen.1007967.g006
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eight Labrador Retrievers for which MCT metastases could not be detected and whom were
still alive 1,000 days post-diagnosis. The dogs genotyped were either heterozygotes (ten dogs:
five with metastatic MCT, and five with non-metastatic MCT), or homozygous for the refer-
ence ‘G’ allele (three dogs with non-metastatic MCT). No association was found between MCT
metastasis and the SNP rs850678541 genotype (Fisher exact test P-value = 0.43) in this small
preliminary dataset.
The SNP rs850678541 alternative allele is also associated with MCT
development in Golden Retrievers
SNP rs850678541 was genotyped in a MCT case-control set of UK Golden Retrievers, a breed that
is both closely related to Labrador Retrievers [35] and has an elevated risk of developing MCTs [2,
4, 19]. Germline DNAs from 37 Golden Retrievers that either currently or previously had a MCT
and 53 dogs aged at least 7 years of age that had never been affected by any form of cancer were
genotyped. SNP rs850678541 demonstrated statistical association with MCT (P-value = 0.01) that
was directionally consistent and of a similar magnitude of effect to that observed in Labrador
Retrievers, and accounted for 5% (pseudo r2) of the MCT trait in Golden Retrievers (Table 5).
The alternative ‘A’ allele was common in this Golden Retriever set (70% of the dogs, including
62% of controls, carried at least one copy, and 26% of the dogs, including 17% of controls, carried
two copies) (Table 5). This allele increases the risk of MCT development by 1.90 x (ratio of hetero-
zygote odds: reference allele homozygote odds; 95% confidence interval 0.65–5.54) when present
as one copy, and by 4.44 x (ratio of alternative allele homozygote odds: reference allele homozy-
gote odds; 95% confidence interval 1.34–14.77) when present as two copies.
SNP rs850678541 was also genotyped in the Border Collie (110 dogs) and Cavalier King
Charles Spaniel (105 dogs), two breeds which are under-represented amongst dogs that
develop MCTs [4, 19]. The alternative ‘A’ allele was present in both breeds at a frequency (Bor-
der Collie: 0.058; Cavalier King Charles Spaniel: 0.38) lower than that in the Labrador
Retriever (0.49) and Golden Retriever (0.48).
The Golden Retriever MCT susceptibility SNP rs851590509 in GNAI2 is
rare in Labrador Retrievers
We investigated if the MCT susceptibility SNP rs851590509 at CFA20: 39080161, which was
previously identified in European Golden Retrievers by Arendt and co-workers [22], is also
Table 5. The association between SNP rs850678541 and/or SNP rs851590509 and MCT in a set of Golden Retrievers.
genotypes No. MCT cases No. controls Odds ratio
(95% CI) P-value
Model fit (pseudo r2)
SNP rs850678541
G/G 7 20 2.11
(1.16–3.86)
0.01
G/A 16 24 0.05
A/A 14 9
SNP rs851590509
G/G 1 14 6.82
(2.91–16.00)
1.5 x 10−7
G/A 9 28 0.23
A/A 27 11
Combined Analysis
N/A 37 53 8.04
(3.17–20.43)
2.6 x 10−8
0.29
CI: confidence interval. N/A: not applicable. The P-values presented were obtained by logistic regression and log likelihood ratio test.
https://doi.org/10.1371/journal.pgen.1007967.t005
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associated with MCTs in Labrador Retrievers. The variant is located in an exon of the GNAI2
gene and causes alternative exon splicing and a truncated protein. We performed TaqMan geno-
typing of rs851590509 in 167 cases and 193 controls from our extended MCT case-control set of
UK Labradors. The alternative ‘A’ ‘risk allele’ of the SNP is rare in Labrador Retrievers (frequency
in the whole set: 0.007), and no association was found with MCTs (Fisher Exact P-value = 0.09).
Arendt et al. also identified a putative MCT susceptibility locus at CFA14:14.7Mb in Golden
Retrievers from the United States (although the most significantly associated SNPs were not
found to be associated with the MCT trait in European Golden Retrievers). A causal variant for
the CFA14:14.7Mb association has yet to be identified, and for this reason we did not screen for
associations between CFA14:14.7Mb SNPs and the MCT trait in our UK Labrador Retriever
cohort.
Combined analysis of the rs850678541 and rs851590509 variants and risk
of MCT in Golden Retrievers
Our next step was to evaluate the extent of the risk conferred by rs850678541 and rs851590509 in
our UK Golden Retriever set of 37 MCT cases and 53 controls. TaqMan genotyping of SNP
rs851590509 in this set showed that the alternative ‘A’ allele is extremely common (83% of the
dogs, including 74% of controls, carried at least one copy, and 42% of the dogs, including 21% of
controls, carried two copies), and has a statistically significant association with MCTs (P-value =
1.5 x 10−7) (Table 5). Furthermore, a combined analysis of rs850678541 and rs851590509 in
this set of Golden Retrievers demonstrated a statistically significant association with MCTs
(P-value = 2.6 x 10−8) and revealed that collectively these variants explain 29% of the MCT trait in
this breed (Table 5). Due to the rarity of the rs851590509 SNP in the Labrador Retriever set we
could not perform a combined analysis of rs851590509 and rs850678541 in this breed.
Discussion
In this study we have identified a synonymous germline variant (‘A’ allele of SNP
rs850678541) in the DSCAM gene that is associated with the elevated risk of MCT develop-
ment in Labrador Retrievers. We revealed that, although the variant has no effect on DSCAM
mRNA expression, it is associated with a significantly reduced DSCAM protein level in
MCTs and in normal skin. The demonstration that intronic variants at loci in the DSCAM
gene that are in LD with SNP rs850678541 do not cause alternative exon splicing (that may be
reflected in a decrease in the level of the full length 196kDa DSCAM protein—UniProtKB
F1PA86_CANLF) affords a strong indication that the SNP rs850678541 alternative allele may
be responsible for the significant reduction in DSCAM protein expression observed in MCTs
and normal skin specimens from Labrador Retrievers homozygous for the alternative allele.
The variant allele is common in Labrador Retrievers, is associated with a per allele increase in
MCT risk of 1.66 x, and is estimated to account for 2% of the MCT trait in the breed.
SNP rs850678541 was also shown to be a risk factor for MCT development in Golden
Retrievers (accounting for 5% of the MCT trait in the breed), suggesting that the variant arose
in a common ancestor at some point prior to divergence of the Labrador and Golden Retriever
breeds. The strength of the association (odds ratio = 2.11) between the SNP and MCTs in our
set of Golden Retrievers suggests that a lack of statistical power may be the reason why an asso-
ciation to SNPs in the vicinity of CFA31 34.7Mb was not detected in the European Golden
Retriever MCT GWAS performed by Arendt and colleagues [22]. An alternative explanation
for this is that the CFA31 SNPs on the canineHD array were not able to ‘capture’ SNP
rs850678541 in Golden Retrievers due to a different haplotype structure in this breed. The
association between the CFA20 SNP rs851590509 and MCTs in European Golden Retrievers
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reported by Arendt and co-workers [22] was reproduced in our set of Golden Retrievers. Sig-
nificantly, our combined analysis showed that collectively SNPs rs850678541 and rs851590509
explain 29% of the MCT trait in Golden Retrievers. In our set of Labrador Retrievers, SNP
rs851590509 was very rare, which did not allow for a combined analysis to be undertaken. To
the best of our knowledge, the SNP rs850678541 described here is currently the only MCT-
associated variant in Labrador Retrievers to be identified, although it is likely that other MCT-
associated variants will be described because our secondary GWAS meta-analysis has sug-
gested associations with other genomic regions. Furthermore, the demonstration that MCT
susceptibility loci are shared by Labrador and Golden Retrievers, suggests that meta-analysis
of genotype data from both breeds may uncover additional MCT susceptibility loci.
A recent study demonstrated the presence of Mendelian disease variants in pedigree dog
breeds for which the disease/an elevated risk of developing the disease had not previously been
reported [36], leading the investigators to speculate that the ‘genetic background’ may affect
how a mutation is manifest. The most notable example is arguably the SOD1:c.118A allele,
homozygotes and heterozygotes of which in 5 breeds are associated with degenerative myelop-
athy. The SOD1:c.118A allele is also present (at up to a high frequency) in many breeds [37]
that are not known to develop degenerative myelopathy, suggesting that the penetrance of the
allele is affected by other genetic or environmental factors. In this study we found that the SNP
rs850678541 alternative ‘A’ allele, which is associated with MCTs in Labrador and Golden
Retrievers, is present at a lower frequency in Border Collies (frequency 12.3 x lower) and Cava-
lier King Charles Spaniels (frequency 1.3 x lower), two breeds that are under-represented
amongst MCT-affected dogs [4, 19]. As MCT susceptibility appears to be complex, the risk
conferred by the SNP rs850678541 alternative ‘A’ allele in Labrador and Golden Retrievers has
to be considered in the context of potential modifying alleles at other MCT susceptibility loci
that may be present in Labrador and Golden Retrievers and absent from other breeds. Indeed,
susceptibility variants have been found to modify the risk of breast cancer development associ-
ated with the BRCA1 and BRCA2 mutations, thereby accounting for the variation in breast
cancer penetrance observed for these mutations in different human families [38]. Extensive
GWAS of human diseases has demonstrated that genetic risk factors underlying complex dis-
eases, such as cancer, comprise both common ancestral risk variants of intermediate effect and
rarer risk variants of higher effect/penetrance [39]. However, it is likely that in the dog, as is
the case for diverse human populations, the impact of these risk variants will depend on both
environmental influences and other genetic risk factors that an individual possesses. In this
study we have identified a common risk variant of intermediate effect that we have shown to
be reproducibly associated with MCTs in two breeds. This suggests that the common disease
common variant hypothesis for human complex disease also holds true in the dog, although
this may vary between breeds. It will ultimately be informative to genotype all subsequently
identified Labrador and Golden Retriever MCT susceptibility variants in low risk breeds to
assist understanding of the contribution of the ‘interaction’ between susceptibility loci to the
elevated risk of MCT development.
For some time, synonymous variants, such as SNP rs850678541, were known as silent, as it
was thought that they had no effect on gene expression and cellular fitness. Genome sequenc-
ing led to the realisation that synonymous codons do not appear with the same frequency in a
genome (a phenomenon known as codon usage bias) and challenged this concept [30]. Conse-
quently, it is now acknowledged that synonymous variants can influence cellular functions
through effects on mRNA stability and processing, translation kinetics and protein folding
[40]. Interestingly, Vedula and co-workers have shown that the diverse functions of β and U
actin homologues are defined by synonymous variants in their nucleotide sequences, and con-
sequent differences in their translation and post-translational modifications dynamics,
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demonstrating that synonymous variants are important factors in the regulation of the func-
tional diversity of protein isoforms in a variety of physiological conditions [41]. With regards
to medical conditions, synonymous mutations have been associated with complex diseases
such as neurological disorders, diabetes and cancer [42]. In a study in which 3,000 tumour
exomes and 300 tumour genomes were analysed it was estimated that 1 in 5–1 in 2 silent muta-
tions were positively selected, and acted as driver mutations in human cancers [43]. With
regard to canine MCTs, the Golden Retriever MCT-associated variant SNP rs851590509 iden-
tified by Arendt and co-workers is also of a synonymous nature [22]. In this case, the synony-
mous variant is located in a splicing site, and was shown to have an effect on splicing [22]. By
contrast, in the present study the synonymous SNP that we have shown to be associated with
MCTs in Labrador and Golden Retrievers (SNP rs850678541) appears to have an effect on the
translation dynamics of the DSCAM gene.
Translation dynamics are affected by the decoding times of each of the codons present in a
transcript [44]. The decoding time of each codon is a function of parameters such as the overall
codon landscape in the transcript, and is also positively correlated with abundance of the cog-
nate tRNA [45]. Transfer RNA abundance varies between different tissues [46], and is posi-
tively correlated with the frequency with which the codon that is cognate to a tRNA is used in
genes that are ‘highly expressed’ in a given tissue [47]. Therefore, a synonymous mutation can
conceivably lead to an increased decoding time and impaired translation of a transcript in a
given tissue if it results in a rarer codon than the ‘wild type’. Indeed, Kirchner and co-workers
identified a synonymous SNP in the cystic fibrosis transmembrane conductance regulator
gene, which resulted in a rare codon, which had a low-frequency cognate tRNA, and decreased
protein expression in bronchial tissue. Remarkably, they showed that increasing the abun-
dance of the tRNA cognate to the mutated codon rescued the protein expression phenotype
associated with the synonymous SNP [48]. We were unable to measure, in our MCT biopsies
and skin specimens, the abundance of the tRNAs cognate to the ‘reference’ (CGC) codon and
alternative (CGU) arginine codon generated by the synonymous variant. This is because tRNA
microarrays are unable to differentiate between these two arginine isoacceptors, and the partial
hydrolysis which is used to overcome the challenges imposed by tRNA secondary and tertiary
structures to build a next generation sequencing library, makes it impossible to differentiate
(and quantify the relative abundances of) the tRNAs by sequencing [49]. Furthermore, a
sequence (canine or human) for the arginine ‘reference codon’ cognate tRNA is not available
in the tRNA database [50], which made the design of primers for a RT-qPCR assay impossible.
Therefore, unfortunately, we were unable to mechanistically correlate the reduced levels of the
DSCAM protein that we observed with the synonymous SNP identified, although we are hope-
ful that future advances in tRNA analysis techniques will enable us to so do. Nevertheless, the
fact that the ‘reference’ CGC codon is nearly three times as frequent as the rs850678541 alter-
native allele-containing CGU codon in a sample of 1,194 canine mRNA transcripts (Kazusa
database [51]; S7 Table) is an indication that the synonymous variant that we identified might
be capable of having a negative effect on the DSCAM gene translation dynamics. Interestingly,
10-fold differences between the translation efficiencies of arginine codons have been demon-
strated in plant chloroplasts where there was parity in codon usage [52].
The DSCAM gene was first characterised as encoding a cell adhesion molecule; a member
of the immunoglobulin superfamily of cell surface proteins, in a study which identified it as a
Down syndrome-related gene [53]. It has an important function in nervous system develop-
ment, and its conservation in arthropods and mammals reflects its role in neural circuitry for-
mation and an innate-immunity function, specific to arthropods [54, 55]. DSCAM has also
been identified as a predisposing locus for Hirschsprung’s disease that is often observed in
association with Down syndrome [56]. SNPs in the DSCAM gene have also been associated
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with idiopathic scoliosis in adolescents [57] and with anxiety and depression disorder [58].
Although a germline SNP in the DSCAM gene has been found to be associated with shortened
overall survival in response to chemotherapy in patients with non-small cell lung cancer [59],
and somatic mutations in this gene have been found in approximately 40 different types of
tumour ([60]; S8 Table), to the best of our knowledge, this is the first report of an association
between a germline variant in the DSCAM gene and susceptibility to cancer.
It is likely to be significant that the development of MCTs in two susceptible canine breeds
has now been associated with germline variants in genes involved in cell-to-cell or cell-to-extra-
cellular matrix (ECM) interactions. MCT development has been associated with a variant (SNP
rs851590509) in the gene of a G-protein subunit (GNAI2), which acts as regulator of different
transmembrane signalling pathways in a study of European Golden Retrievers; and with variants
located in a region containing genes that encode hyaluronidase, an enzyme which cleaves a com-
ponent of the MCT ECM, in a study of US Golden Retrievers [22]. Strikingly, in a study of US
Labrador Retrievers, MCT development was found to be associated with a variant suspected to
be located in a gene encoding a subunit of integrin, a cell adhesion and signalling molecule [23].
Our finding that MCT development is associated with a variant in the DSCAM gene in European
pet Labrador and Golden Retrievers is additional evidence that alterations in the interaction of
mast cells with the microenvironment is an important step in MCT tumorigenesis. More specifi-
cally, in the case of Labrador Retrievers, it provides compelling evidence that alterations in cell
adhesion molecules represent an important risk factor for MCT development. Indeed, it has
been shown that cell adhesion molecules, such as E-Cadherin, and the Ig superfamily member
CADM1, can act as tumour suppressors mainly through contact inhibition of cell proliferation
[61–64]. For dogs affected by MCTs, there was a trend for those whose MCTs displayed a
reduced expression level of SynCAM, a cell adhesion molecule of the immunoglobulin super-
family, to be more likely to suffer MCT-related death [65]. In this study we found no association
between SNP rs850678541 alternative allele and MCT metastasis in Labrador Retrievers. How-
ever, the sample set was of limited size and the thirteen dogs for whom definitive confirmation
of ‘MCT metastatic disease status’ was achievable did not include dogs homozygous for the SNP
rs850678541 alternative (variant) allele, a significant exclusion given that the ten-fold reduction
in the level of DSCAM protein expression was only observed in MCTs and skin biopsies from
dogs which are homozygous for the SNP rs850678541 alternative allele. Consequently, a much
larger investigation featuring dogs with all three SNP rs850678541 genotypes, and affected by
both metastasising and non-metastasising MCTs, is merited. Illustration of the likely importance
of dysregulation of cell adhesion in human mastocytosis is the fact that the pathway activated by
the c-kit receptor, which is frequently found somatically mutated in human mastocytosis, also
regulates mast cell adhesion, in addition to survival and other cellular processes [66, 67].
In conclusion, the results presented here demonstrate the importance of retaining synony-
mous variants as possible functional candidates when screening for germline susceptibility loci
for complex diseases, such as cancer. In addition, through identifying a common genetic risk
factor for MCT development in Labrador and Golden Retrievers, the contribution of dysregu-
lation of cell adhesion to MCT pathogenesis has been demonstrated.
Methods
Ethics statement
The blood samples and buccal swabs used in the study were collected, retained and used for
research with the written consent of the dogs’ owners. Buccal swabs were collected by dogs’
owners, and blood samples were collected by clinicians with the consent of dogs’ owners.
Blood samples from UK dogs were surplus to that collected for a clinical reason, or as part of a
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health check. MCT biopsies were dissected (with the consent of dogs’ owners) from MCTs
which were surgically removed in the course of standard treatment protocols. Biopsies of nor-
mal skin were excised post-mortem from dogs whose bodies had been donated for research by
their owners. The research study, and the protocol by which samples were collected for the
study, were approved by the ethics committees of the participating institutions: AHT Clinical
Ethics Committee, project number AHT_07–11; Committee for Animal Care at the Massachu-
setts Institute of Technology, approval number MIT CAC 0910-074-13; Uppsala Animal Ethi-
cal Board, approval number C2-12; Animal Experiments Committee of the Academic
Biomedical Centre, Utrecht, The Netherlands, experimental protocol ID 2007.111.08.110.
Germline DNA samples
Buccal swabs and blood samples were collected from Labrador and Golden Retrievers con-
firmed by histopathology to have/have had a MCT, and Labrador and Golden Retrievers aged
at least 7 years old whom had never been affected by any form of cancer. For GWAS, Labrador
Retriever samples were collected by the Animal Health Trust in the UK (153 samples), the
Broad Institute in the United States (108 samples), and the University of Utrecht in the Nether-
lands (77 samples) (S9 Table). For genotyping of candidate germline MCT susceptibility vari-
ants, 407 Labrador Retriever samples were collected by the Animal Health Trust in the UK (S9
Table). All Golden Retriever, Border Collie and Cavalier King Charles Spaniel samples were
collected by the Animal Health Trust in the UK. Genomic DNA was isolated from buccal
swabs by phenol-chloroform extraction [68], and from whole blood using the Nucleon Geno-
mic DNA Extraction Kit (Tepnel Life Sciences), or the QIAamp DNA Blood Midi Kit
(Qiagen).
DNA, RNA and protein extraction from RNAlater-preserved tissue
biopsies
This protocol is available on the protocols.io database (dx.doi.org/10.17504/protocols.io.sq2e-
dye). Seventeen RNAlater (ThermoFisher Scientific)-preserved MCT (Biopsies#1–17 in Fig 2)
and three post-mortem normal skin biopsies (Biopsies#18–20 in Fig 2), in the form of 3mm
cubes, were homogenised in 700μl of Qiazol (Qiagen) by shaking with 2 x 7mm stainless steel
beads at 30Hz in a TissueLyser LT (Qiagen) for 10 min at room temperature. Chloroform
(140μl) was added to each homogenate and the aqueous phase recovered following centrifuga-
tion (12,000 x g for 15 min at 4˚C) was used for RNA extraction with the miRNeasy Mini Kit
(Qiagen), following the manufacturer’s instructions.
The interphase and organic phase were used for DNA and protein extraction. Briefly, DNA
was precipitated with 100% (v/v) ethanol, and washed successively in 0.1M sodium citrate and
75% (v/v) ethanol before being resuspended in 8mM sodium hydroxide. Following DNA pre-
cipitation, protein was precipitated from the interphase and organic phase with 100% (v/v) iso-
propanol, washed successively in 0.3M guanidine-hydrochloride in 95% ethanol, and 75% (v/
v) ethanol, and resuspended in 10M urea, 1% (v/v) 2-mercaptoethanol.
Genome wide association analysis (GWAS)
Genotyping was performed at the Centre National De Genotypage, Paris, France. Genomic
DNA (200ng at 100ng/μl) was genotyped using the Infinium HD Ultra Assay (Illumina) and
the canineHD array (Illumina), which comprises 173,662 SNPs spanning the canine genome
at a density of around 70 SNPs per Mb [69]. GWAS datasets were analysed individually by
country and genotyping run before meta-analysis to preserve data quality and reduce possible
biases caused by different sample preparation procedures in different laboratories, and
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possible population effects between countries (case-control sets did not all approximate to a
1:1 ratio). The number of cases and controls in each individual dataset following sample qual-
ity control (QC) filtering (dropping individuals with a SNP call rate of< 90%) are shown in S1
Table. SNP QC filtering was conducted in each of the individual datasets independently. SNPs
that had a minor allele frequency (MAF) of<5% and/or call rate of<97% in each dataset were
excluded.
Within each dataset we visually assessed the extent of population substructure using multi-
dimensional scaling plots in two dimensions, and by calculating genomic inflation factors,
which were estimated for each dataset independently from the median of the Χ2 tests of all
SNPs tested following QC (S1 Table). From examination of the multidimensional scaling plot
for the “Set 1” dataset it was apparent that there were two distinct clusters of dogs within this
dataset there were 28 MCT cases and 20 controls that were Guiding Eye for the Blind Dogs (S6
Fig). As these dogs originate from a line of Labradors distinct from the general pet population
we postulated that they could be potential confounders in the GWAS analyses. We therefore
excluded Guiding Eye for the Blind Dogs from this dataset and from future analyses. Unad-
justed GWAS analyses were conducted using PLINK [70] and analyses correcting for popula-
tion stratification were performed using GEMMA [71].
Genome-wide meta-analyses were conducted using SNPs that had passed QC within two or
more individual datasets (S2 Fig), and for the population-adjusted meta-analysis (S3 Fig) using
only SNPs in common in all six datasets.
Sequence capture, next generation sequencing, and variant identification
Genomic regions implicated by GWAS as containing MCT susceptibility loci were captured
from DNA samples from affected and unaffected Labrador Retrievers using SureSelect Target
Enrichment System RNA oligonucleotide baits (Agilent) from libraries prepared using the
TruSeq DNA Sample Preparation Kit (Illumina index set A; Illumina). Enriched libraries were
sequenced using a HiSeq 2000 (100bp paired-end sequencing, approximately 30-fold coverage)
(Illumina). A Genome Analysis Toolkit (GATK)-based pipeline [72] was employed to align
Fastq file format sequence reads to the CanFam3.1 reference Boxer genome and detect SNVs
and indels. The potential functional impact of each variant was predicted using Variant Effect
Predictor [73] and SIFT [25]. A locus harbouring one or more allelic variants was considered
to be a candidate MCT susceptibility locus, and selected for further analysis, if it fulfilled both
of the following criteria:
1. Locus position: exon, including UTRs, and predicted to be deleterious or non-deleterious,
OR splice region
AND
2. Segregation: One allele is present as at least one copy in at least one case and is not present
in any of the controls [i.e. (a) Biallelelic loci: one allele can be present in both cases and
controls, but the second allele must be unique to the cases; (b) Multi-allele loci: multiple
alleles can be present in both cases and controls, but one allele must be unique to the cases)
Genotyping of candidate MCT susceptibility variants
All CFA31 candidate MCT susceptibility variants were typed in Labrador Retrievers, and SNP
rs850678541 was typed in Golden Retrievers, Border Collies and Cavalier King Charles Span-
iels. For SNPs, TaqMan Genotyping Assays (ThermoFisher Scientific) were designed (S8
Table) from variant-containing genomic DNA sequences in which known SNPs, repeat
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sequences, and stretches of sequence displaying significant similarity to other regions of the
genome were masked. TaqMan Genotyping Assays were 10μl reactions performed using 1μl of
genomic DNA, according to the manufacturer’s instructions. The TaqMan Genotyping Master
Mix (ThermoFisher Scientific) was used routinely, but the TaqPath ProAmp Master Mix
(ThermoFisher Scientific) was employed when there was an indication of PCR inhibition.
Thermocycling was performed in a StepOne Plus Machine (ThermoFisher Scientific), and the
results analysed using TaqMan Genotyper Software (ThermoFisher Scientific). Every genotyp-
ing run featured DNA samples of known genotype as positive controls, and two non-template
negative controls.
The indel variant at CFA31:34667505 was genotyped through DNA fragment analysis.
Amplification and fluorescent end-labelling of target fragments was achieved using 10μl PCR
reactions containing 2μl of 1:100 diluted genomic DNA sample, 0.2μM of each of a forward
FAM-labelled forward primer and an unlabelled reverse primer (S9 Table), 4 x 0.2mM dNTPs
and 0.25 units of HotStarTaq DNA Polymerase (Qiagen). Thermocycling was performed in a
T100 Thermal Cycler (BioRad) using the following parameters: 95˚C, 15 min; (94˚C, 30s;
60˚C, 60s; 72˚C, 30s) x 35; 72˚C, 10 min. A microlitre of each labelled PCR product was mixed
with 10μl of HiDi formamide (ThermoFisher Scientific) and 0.4μl of the ABI GeneScan
400HD ROX size standard (ThermoFisher Scientific) and loaded into an ABI 3130xl Genetic
Analyser machine, using POP_7 polymer (ThermoFisher Scientific) as the separation matrix.
The resulting data were analysed using the ABI GeneMapper software (ThermoFisher Scien-
tific). Every genotyping run featured positive and negative controls.
Genotyping of CFA20 SNP rs851590509 in Labrador and Golden
Retrievers
The Golden Retriever MCT-associated SNP rs851590509, identified by Arendt and colleagues
[22], was genotyped in a set of Labrador and Golden Retrievers by TaqMan assay (Thermo-
fisher Scientific) (S8 Table). Genotyping was performed using 10μl reactions, incorporating
1μl of genomic DNA and the TaqPath ProAmp Master Mix (ThermoFisher Scientific), accord-
ing to the manufacturer’s instructions. Thermocycling was performed in a StepOne Plus
Machine (ThermoFisher Scientific), and the results analysed using TaqMan Genotyper Soft-
ware (ThermoFisher Scientific). Every genotyping run featured two non-template negative
controls, and a positive control (a sample of known genotype).
Linkage Disequilibrium (LD) analysis
Variant-harbouring loci in LD with the SNP rs850678541 were identified using genotypes
derived from the resequencing data obtained for 12 Labrador Retrievers (six cases and six con-
trols). Haplotype analysis of biallelic loci was performed using Haploview, version 4.2 [74].
The software’s “Tagger” function [75], with a r2 threshold of 0.8, was used to identify biallelic
variants in LD with the rs850678541 variant. The identification of multiallelic loci in LD with
SNP rs850678541 was performed in two steps. The first step involved the identification of loci
for which one allele had a frequency = the frequency of the SNP rs850678541 alternative (vari-
ant) allele ± 20%. In the second step, the genotypes at the loci selected in step one were com-
pared to the genotype of the SNP rs850678541 locus, in order to identify those that displayed
�1 segregation event from this locus.
Reverse transcription-quantitative PCR (RT-qPCR)
MCT RNAs with RIN values�8.0 (Agilent Bioanalyser RNA 6000 Nano Kit; Agilent) were
treated with 1.5U/μg RNA of heparinase I (Sigma-Aldrich) in 5mM Tris-HCl (pH 7.5), 1mM
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CaCl2 at 25˚C for 3h in order to eliminate heparin, a reverse transcription and PCR inhibitor
commonly found in mast cells [31]. cDNA was prepared from 2.44μg of heparinase- treated
RNA, using the High Capacity RNA to cDNA kit (ThermoFisher Scientific), following the manu-
facturer’s instructions. Each MCT cDNA sample was assessed for the presence of PCR (and
potentially reverse transcription) inhibitors by adding an equal amount of a synthetic Solanum
tuberosum-derived amplicon to each sample, and screening for differences between the synthetic
amplicon quantification cycle (Cq) value obtained for each cDNA sample upon PCR amplifica-
tion [76]. PCR reactions (10μl), comprising 1μl of cDNA, 1 x SsoAdvanced SYBR Green Master
Mix (BioRad), 1.33fM of SPUD amplicon (S9 Table), and 0.3μM of forward and reverse SPUD
primers (S9 Table), were run in an ABI StepOne Plus machine (ThermoFisher Scientific) using
the following program: 98˚C, 2min; (98˚C, 5s; 60˚C, 30s) x 40; Melt Curve program. Triplicate
PCR assays were performed for each MCT cDNA sample and a mean Cq value calculated.
DSCAM mRNA expression was assayed using 10μl PCR reactions, comprising 1μl of
cDNA, 1 x PowerUp SYBR Green Master Mix (ThermoFisher Scientific) and 0.3μM of forward
and reverse DSCAM primers (S9 Table), run in an ABI StepOne Plus machine (ThermoFisher
Scientific) with the following parameters: 50˚C, 2 min; 95˚C, 2 min; (95˚C, 3s; 60˚C, 30s) x 40;
Melt Curve program. Triplicate PCR assays were performed for each MCT cDNA sample. To
enable normalisation of DSCAM expression values, the expression level of a 70bp fragment of a
SINE [77] that occurs in the 3’-untranslated region of hundreds of canine mRNAs, in each
MCT RNA sample was also assayed (performing triplicate reactions for each cDNA sample). A
repeat sequence that is present in hundreds of copies in any canine tissue sample transcriptome
will effectively display invariant expression across all samples of a given tissue type ensuring reli-
able normalisation of RT-qPCR-derived gene expression data [78]. The SINE PCR reaction
master mix was subject to UV irradiation (302nm) for 5 min prior to the addition of the SINE
PCR primers (S9 Table), but the PCR reaction components and thermocycling parameters were
as used for the DSCAM mRNA assays. For each MCT cDNA sample, a mean Cq value was
determined for each PCR amplicon from the Cq values obtained for the triplicate PCR reactions
by the StepOne Plus software (Thermofisher Scientific). The mean DSCAM Cq value for each
MCT cDNA sample was imported into qbase+ (Biogazelle), which generated a relative measure
of DSCAM expression (a calibrated normalised relative quantity) for each MCT cDNA sample,
using the mean SINE Cq value obtained for the same cDNA sample [79].
End point PCR assays
Nested end point PCR assays were performed to screen for possible alternative splicing of
DSCAM mRNAs. For the E14-15 Assay, first round PCR reactions (20μl) featured 1μl of
cDNA, 1 x HotStar HiFidelity PCR buffer (Qiagen), 1μM of both the ‘external’ (A) forward and
reverse ‘external’ (A) primers (S9 Table), and 1 unit of HotStar Taq HiFidelity DNA Polymerase
(Qiagen). Thermocycling was performed as follows: 95˚C, 5 min; (94˚C, 15s; 52˚C, 60s; 72˚C, 1
min) x 40; 72˚C, 10 min,. A 1μl aliquot of a 1 : 100 dilution of each first round PCR product was
used in a 20μl second round PCR reaction comprising 1 x HotStar HiFidelity PCR buffer (Qia-
gen), 1μM of both the ‘internal’ (B) forward and reverse primers (S9 Table), and 1 unit of Hot-
Star Taq HiFidelity DNA Polymerase (Qiagen). The thermocycling parameters were 95˚C, 5
min; (94˚C, 15s; 51˚C, 60s; 72˚C, 60s) x 30; 72˚C, 10 min. For the E15-17 Assay, first round
PCR reactions (20μl) featured 1μl of cDNA, 1 x HotStar Taq PCR buffer (Qiagen), 1 x Q-Solu-
tion (Qiagen), 0.5μM of both the ‘external’ (A) forward and reverse primers (S9 Table), 0.3mM
of each of 4 x dNTPs (Qiagen), 2 units of HotStar Taq DNA Polymerase (Qiagen), and 0.08
units of HotStar HiFidelity Taq DNA Polymerase (Qiagen). Thermocycling was performed as
follows: 95˚C, 2 min; (94˚C, 10s; 56˚C, 60s; 68˚C, 6 min 30s) x 40. A 1μl aliquot of a 1 : 100
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dilution of each first round PCR product was used in a 20μl second round PCR reaction com-
prising 1 x HotStar Taq PCR buffer (Qiagen), 1 x Q-Solution (Qiagen), 0.5μM of both the ‘inter-
nal’ (B) forward and reverse primers (S9 Table), 0.3mM of each of 4 x dNTPs (Qiagen), 2 units
of HotStar Taq DNA Polymerase (Qiagen), and 0.08 units of HotStar HiFidelity Taq DNA Poly-
merase (Qiagen). Thermocycling was performed as follows: 95˚C, 2 min; (94˚C, 10s; 59˚C, 60s;
68˚C, 6 min 30s) x 40. Second round PCR reaction products were analysed by 2% agarose gel
electrophoresis (E14-15 Assay) and by 0.8% agarose gel electrophoresis (E15-17 Assay), respec-
tively. Images were captured using the Alpha Imager (Alpha Innotech).
Semi-quantitative western blot
Protein samples were quantified using the Bradford Assay. Prior to polyacrylamide gel electro-
phoresis, protein samples were mixed with 4 x NuPage loading buffer (ThermoFisher Scien-
tific), incubated at 70˚C for 10 min, and on ice for 5 min. Twenty-five micrograms of each
protein sample and 10μl of the Precision Plus Western C protein standard (BioRad) were
loaded onto a TGX Stain-Free 4–20% gradient gel (BioRad) and electrophoresed at 200kV for
40 min in 1 x Tris-Glycine SDS PAGE Buffer (National Diagnostics). A single protein sample
was included on every gel for use as an inter-western blot calibrator. Prior to transfer of pro-
teins to a membrane, a gel was exposed to 365nm UV for 2.5–5 min in order to activate the
Stain-Free technology. Proteins were transferred from the gel to a 0.45μm nitrocellulose mem-
brane (BioRad) in a Mini Trans-Blot Cell system, at 100kV for 1 hour in Tris-Glycine transfer
buffer, containing 20% (v/v) methanol.
The Stain-Free total protein image of a protein blot was detected under UV light using the
Alpha Imager (Alpha Innotech). The membrane was subsequently agitated in Ponceau S solu-
tion (Sigma Aldrich) for 1 min, washed 3 x with MilliQ water and visualised under white
reflective light in the Alpha Imager (Alpha Innotech). Ponceau S stain was removed by 3 x
washes in MilliQ water, and a membrane gently agitated in Blocking Solution (WesternBreeze
Chromogenic Western Blot Immunodetection Kit; ThermoFisher Scientific) for 30 min, and
incubated in a 1: 1000 dilution of anti-DSCAM antibody (abcamab85362, which has a highly
conserved human DSCAM protein sequence as epitope) in Blocking solution at 4˚C overnight.
The membrane was washed 3 x (5 min each) with the Antibody Wash Solution (Wester-
nBreeze Chromogenic Western Blot Immunodetection Kit; ThermoFisher Scientific), incu-
bated with a 1 : 1000 dilution of alkaline phosphatase-conjugated Goat anti-Rabbit IgG (H+L)
secondary antibody (ThermoFisher Scientific) in Blocking Solution for 30 min, washed 3 x (5
min each) with the Antibody Wash Solution, and finally incubated with BCIP/NBT Chromo-
genic substrate (WesternBreeze Chromogenic Western Blot Immunodetection Kit; Thermo-
Fisher Scientific) for 1–5 min. Images were captured, under reflective white light, on the Alpha
Imager (Alpha Innotech). The total protein and DSCAM staining membrane images were
imported into the ImageLab software (BioRad) for analysis and quantification. Normalisation
of the DSCAM level in each sample involved reference to the total quantity of protein detected
(by Ponceau S or the Stain-Free technology) in the sample, and inter-membrane calibration
using the ratio of DSCAM protein quantity/total protein quantity measured for the 25μg pro-
tein sample loaded onto every gel.
Statistical analysis
GWAS. Analyses were performed using STATA 10.0 (College Station, TX, USA) using a
fixed effects model and inverse-variance weighted averages of either the logarithm of the odds
ratios from PLINK and their standard errors (population-unadjusted meta-analyses, Fig 1 and
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S1 Fig), or of beta coefficients and standard errors using GEMMA (S3 Fig). Heterogeneity was
assessed using the Q statistic.
Association analysis between MCTs (Labrador and Golden Retrievers) and candidate
MCT susceptibility variants. Association analyses were conducted in STATA 10.0. SNPs
were analysed using logistic regression and log likelihood ratio tests using a linear per allele
model. Indel association analysis was performed using the Fisher’s exact test using data coded
in both a genotypic and allelic form. The association between MCT and SNP rs851590509 in
the Labrador Retriever was tested using the Fisher’s exact test due to the rarity of the variant in
this breed. For the Golden Retriever, logistic regression and log likelihood ratio tests were used
to test a statistical model comprising SNPs rs851590509 and rs850678541 with MCT to provide
an overall odds ratio, 95% confidence interval and P-value. Logistic regression was used to
compute McFadden’s pseudo r2; i.e. goodness of model fit for tested variants, and a model con-
taining both SNPs rs851590509 and rs850678541 combined.
Quantitative analysis of DSCAM mRNA expression by RT-qPCR. Statistical analysis
featured comparisons between the relative measures of DSCAM mRNA expression (SINE-nor-
malised DSCAM mRNA expression value) of individual MCT biopsies belonging to the three
genotype groups: (a) homozygous for the SNP rs850678541 reference ‘G’ allele, (b) homozygous
for the SNP rs850678541 alternative ‘A’ allele, and (c) heterozygous. Applying non-parametric
tests on the assumption of non-normal distributions of relative DSCAM mRNA expression val-
ues, the Kruskal-Wallis test was employed to compare DSCAM mRNA expression between the
three genotype groups, and the Mann-Whitney U test (two-tailed) employed to compare
DSCAM mRNA expression between pairwise combinations of the three genotype groups.
Quantitative analysis of DSCAM protein expression by semi-quantitative western
blot. Statistical analysis featured comparisons between the relative measures of DSCAM pro-
tein expression [DSCAM protein expression value normalised using a) total quantity of the
protein sample concerned loaded onto a gel, and then b) inter-membrane calibrator of indi-
vidual MCT biopsies] belonging to the three genotype groups: (a) homozygous for the SNP
rs850678541 reference ‘G’ allele, (b) homozygous for the SNP rs850678541 alternative ‘A’
allele, and (c) heterozygous. Applying non-parametric tests on the assumption of non-normal
distributions of relative DSCAM protein expression values, the Kruskal-Wallis test was
employed to compare DSCAM protein expression between the three genotype groups, and the
Mann-Whitney U test (two-tailed) employed to compare DSCAM protein expression between
pairwise combinations of the three genotype groups.
Supporting information
S1 Table. The numbers of cases and controls, and genomic inflation factors, for individual
GWAS datasets. #Number of cases and controls and genomic inflation factors for GWAS
dataset before exclusion of Guiding Eye for the Blind Dogs. �Number of control dogs before
exclusion, in the meta-analysis including Sets 1–6, of one individual that subsequent to geno-
typing had been reported as being affected by cancer (not MCT).
(TIF)
S2 Table. The number of DNA samples from Labrador Retrievers with a MCT or without a
MCT (Control) used for candidate MCT susceptibility loci genotyping. The percentage of
DNA samples that were successfully genotyped by each assay is indicated.
(TIF)
S3 Table. The results obtained for the SPUD assay for detection of reverse transcription
and/or PCR inhibitors in MCT biopsy RNA samples. SNP rs850678541 genotypes are
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represented by: ALT/ALT—Alternative (variant) ‘A’ allele homozygote; REF/REF—Reference
‘G’ allele homozygote; REF/ALT—GA heterozygote.
(TIF)
S4 Table. Raw quantitative RT-PCR data.
(TIF)
S5 Table. Raw western blot data.
(TIF)
S6 Table. The 19 x DSCAM biallelic variants and three multiallelic variants shown to be in
LD with SNP rs850678541. The table containing the biallelic variants shows the r2 values
obtained from analysis performed using the “Tagger” function of Haploview, using a r2 thresh-
old of 0.8 and SNP rs850678541 as a tagger. The variants’ locations in the DSCAM gene are
also listed. Intron 14–15—the variant is located in the intron between exons 14 and 15; Intron
15–16—the variant is located in the intron between exons 15 and 16.
(TIF)
S7 Table. Codon usage information for the Arginine (R) synonymous codon family,
extracted from the Kazusa database of codon usages [51], based on 1,194 canine tran-
scripts. Information pertaining to the reference CGC codon is highlighted in green, and to the
alternative CGT codon is highlighted in yellow.
(TIF)
S8 Table. Tissue distribution of somatic mutations in the DSCAM gene found in human
cancers. Source: COSMIC database [60].
(TIF)
S9 Table. Labrador Retriever sample sets used in the GWAS and candidate MCT suscepti-
bility variant TaqMan genotyping. M: Male; F: Female; (N): neutered; NA: Not available; N/
A: Not applicable.
(TIF)
S10 Table. Probes and PCR primers used in custom TaqMan genotyping assays.
(TIF)
S11 Table. PCR assay reagents used for indel genotyping, screening for reverse transcrip-
tion/PCR inhibitors, and assay of DSCAM expression and alternative splicing.
(TIF)
S1 Fig. QQ plots for GWAS meta-analysis of three Labrador Retriever datasets (Sets 1–3).
Red spots denote chi-squared values expected under the null for each of the number of SNPs
tested; blue spots denote the observed chi-squared values for each SNP.
(TIF)
S2 Fig. GWAS meta-analysis of MCT in the Labrador Retriever. A. Manhattan plot of a
combined analysis of 173 cases and 112 controls from six case-control sets. Analyses
comprised 118,628 SNPs. The horizontal red line denotes the genome-wide association
threshold based on Bonferroni correction for 118,628 tests (P-value = 4.2 x 10−7). The plot
was generated using Haploview version 4.2 [74]. B. QQ plot for GWAS meta-analysis of six
Labrador Retriever datasets. Red spots denote chi-squared values expected under the null for
each of the number of SNPs tested; blue spots denote the observed chi-squared values for each
SNP.
(TIF)
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S3 Fig. GWAS meta-analysis of MCT in the Labrador Retriever adjusted for population
stratification. A. Manhattan plot of a combined analysis of 173 cases and 112 controls from
six case-control sets. Analyses comprised 87,632 SNPs. The horizontal red line denotes the
genome-wide association threshold based on Bonferroni correction for 87,632 tests (P-
value = 5.7 x 10−7). The plot was generated using Haploview version 4.2 [74]. B. QQ plot for
GWAS meta-analysis of six Labrador Retriever datasets after adjustment for population strati-
fication. Red spots denote chi-squared values expected under the null for each of the number
of SNPs tested; blue spots denote the observed chi-squared values for each SNP.
(TIF)
S4 Fig. Total protein images (obtained through either Stain-Free technology or Ponceau
staining) of protein samples obtained from Labrador Retriever MCT biopsies. MCT biop-
sies #2, 3, 9 and 11 were not utilised for assay of DSCAM protein expression because the pres-
ence of an intensely staining ~15kDa band in each protein sample suggested significant
protein degradation. The ~15kda band was significantly ‘weaker’ in the MCT biopsy #6 pro-
tein sample that was employed as an inter-membrane calibrator (for normalisation of DSCAM
protein levels).
(TIF)
S5 Fig. A. Whole western blot images of DSCAM antibody staining and total protein
staining (through Ponceau staining and Stain-Free technology) of protein samples
extracted from Labrador Retriever MCT biopsies (#1–17) and normal skin biopsies (#18–
20). Sample number colours indicate SNP rs850678541 genotype: Red = Alt/Alt [Alternative
(variant) ‘A’ allele homozygote]; Green = Ref/Alt [G/A heterozygote]; Blue = Ref/Ref [Refer-
ence ‘G’ allele homozygote]. B. Bar charts showing the DSCAM level in each MCT biopsy
normalised by the total quantity of the MCT biopsy protein (assayed by the Stain-Free technol-
ogy) present on the membrane. The biopsies are grouped according to their SNP rs850678541
genotype. �P�0.05 (Mann-Whitney U test). C. Bar charts showing the mean DSCAM protein
level +/- SD of each MCT biopsy SNP rs850678541 genotype group. Error bars represent stan-
dard deviations. D. Bar charts showing the DSCAM level in each normal skin biopsy normal-
ised by the total quantity of the normal skin biopsy protein (assayed by the Stain-Free
technology) present on the membrane. The bars are coloured according to the normal skin
biopsy SNP rs850678541 genotype.
(TIF)
S6 Fig. Multidimensional scaling plot showing that the Guiding Eye for the Blind Dogs
form a distinct cluster in Set 1.
(TIF)
Acknowledgments
We are indebted to the dog owners who submitted samples from their dogs for the research
study. We are also very grateful for the support of The Labrador Club of Great Britain and the
Nederlandse Labrador Vereniging. We express our gratitude to Mike Boursnell and Oliver
Forman (Canine Genetics Group, Animal Health Trust) who implemented the GATK pipeline
for variant discovery and annotation, which was used to identify variants within targeted re-
sequencing data.
Author Contributions
Conceptualization: Sue Murphy, Kerstin Lindblad-Toh, Mike Starkey.
A synonymous variant associated with mast cell tumours in Labrador and Golden Retrievers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007967 March 22, 2019 28 / 33
Data curation: Lara Compston-Garnett, Sally L. Ricketts.
Formal analysis: Deborah Biasoli, Lara Compston-Garnett, Sally L. Ricketts.
Funding acquisition: Mike Starkey.
Investigation: Deborah Biasoli, Lara Compston-Garnett, Sally L. Ricketts, Zeynep Birand,
Celine Courtay-Cahen, Elena Fineberg.
Methodology: Mike Starkey.
Project administration: Mike Starkey.
Resources: Kim Boerkamp, Michele Koltookian, Sue Murphy.
Supervision: Mike Starkey.
Visualization: Deborah Biasoli, Sally L. Ricketts.
Writing – original draft: Deborah Biasoli, Sally L. Ricketts, Mike Starkey.
Writing – review & editing: Deborah Biasoli, Lara Compston-Garnett, Zeynep Birand, Celine
Courtay-Cahen, Elena Fineberg, Maja Arendt, Kim Boerkamp, Malin Melin, Michele Kol-
tookian, Sue Murphy, Gerard Rutteman, Kerstin Lindblad-Toh, Mike Starkey.
References
1. Welle MM, Bley CR, Howard J, Rufenacht S. Canine mast cell tumours: a review of the pathogenesis,
clinical features, pathology and treatment. Vet Dermatol. 2008; 19(6):321–39. https://doi.org/10.1111/j.
1365-3164.2008.00694.x PMID: 18980632.
2. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL. Canine neoplasia in the UK: estimates of inci-
dence rates from a population of insured dogs. J Small Anim Pract. 2002; 43(6):240–6. PMID:
12074288.
3. O’Connell K, Thomson M. Evaluation of prognostic indicators in dogs with multiple, simultaneously
occurring cutaneous mast cell tumours: 63 cases. Vet Comp Oncol. 2013; 11(1):51–62. https://doi.org/
10.1111/j.1476-5829.2011.00301.x PMID: 22235766.
4. Shoop SJ, Marlow S, Church DB, English K, McGreevy PD, Stell AJ, et al. Prevalence and risk factors
for mast cell tumours in dogs in England. Canine Genet Epidemiol. 2015; 2:1. https://doi.org/10.1186/
2052-6687-2-1 PMID: 26401329; PubMed Central PMCID: PMCPMC4579370.
5. Mochizuki H, Motsinger-Reif A, Bettini C, Moroff S, Breen M. Association of breed and histopathological
grade in canine mast cell tumours. Vet Comp Oncol. 2017; 15(3):829–39. https://doi.org/10.1111/vco.
12225 PMID: 27198171.
6. Dobson JM, Scase TJ. Advances in the diagnosis and management of cutaneous mast cell tumours in
dogs. J Small Anim Pract. 2007; 48(8):424–31. https://doi.org/10.1111/j.1748-5827.2007.00366.x
PMID: 17559522.
7. Ranieri G, Marech I, Pantaleo M, Piccinno M, Roncetti M, Mutinati M, et al. In vivo model for mastocyto-
sis: A comparative review. Crit Rev Oncol Hematol. 2015; 93(3):159–69. https://doi.org/10.1016/j.
critrevonc.2014.10.010 PMID: 25465741.
8. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene
c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987; 6(11):3341–
51. PMID: 2448137.
9. Gil da Costa RM. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours:
From laboratory to clinic. Vet J. 2015; 205(1):5–10. https://doi.org/10.1016/j.tvjl.2015.05.002 PMID:
26021891.
10. Chatterjee A, Ghosh J, Kapur R. Mastocytosis: a mutated KIT receptor induced myeloproliferative disor-
der. Oncotarget. 2015; 6(21):18250–64. https://doi.org/10.18632/oncotarget.4213 PMID: 26158763;
PubMed Central PMCID: PMCPMC4621888.
11. Longley BJ Jr., Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al. Activating and dominant inactivat-
ing c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad
Sci U S A. 1999; 96(4):1609–14. PMID: 9990072; PubMed Central PMCID: PMCPMC15534.
A synonymous variant associated with mast cell tumours in Labrador and Golden Retrievers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007967 March 22, 2019 29 / 33
12. Mochizuki H, Thomas R, Moroff S, Breen M. Genomic profiling of canine mast cell tumors identifies
DNA copy number aberrations associated with KIT mutations and high histological grade. Chromosome
Res. 2017; 25(2):129–43. https://doi.org/10.1007/s10577-016-9543-7 PMID: 28058543.
13. Blackwood L, Murphy S, Buracco P, De Vos JP, De Fornel-Thibaud P, Hirschberger J, et al. European
consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol. 2012; 10(3):e1–e29.
https://doi.org/10.1111/j.1476-5829.2012.00341.x PMID: 22882486.
14. Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Leuk Res. 2011; 35(9):1143–52. https://doi.org/10.1016/j.leukres.2011.05.006 PMID: 21641642.
15. Letard S, Yang Y, Hanssens K, Palmerini F, Leventhal PS, Guery S, et al. Gain-of-function mutations in
the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008; 6
(7):1137–45. https://doi.org/10.1158/1541-7786.MCR-08-0067 PMID: 18644978.
16. Molderings GJ. The genetic basis of mast cell activation disease—looking through a glass darkly. Crit Rev
Oncol Hematol. 2015; 93(2):75–89. https://doi.org/10.1016/j.critrevonc.2014.09.001 PMID: 25305106.
17. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging
treatment concepts. Blood. 2017; 129(11):1420–7. https://doi.org/10.1182/blood-2016-09-731893
PMID: 28031180; PubMed Central PMCID: PMCPMC5356454.
18. Murphy S. Canine Mast Cell Tumours: A Retrospective Study: University of Birmingham; 2001.
19. Warland J, Dobson J. Breed predispositions in canine mast cell tumour: a single centre experience in
the United Kingdom. Vet J. 2013; 197(2):496–8. https://doi.org/10.1016/j.tvjl.2013.02.017 PMID:
23583004.
20. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, et al. Genome sequence,
comparative analysis and haplotype structure of the domestic dog. Nature. 2005; 438(7069):803–19.
https://doi.org/10.1038/nature04338 PMID: 16341006.
21. Karlsson EK, Baranowska I, Wade CM, Salmon Hillbertz NH, Zody MC, Anderson N, et al. Efficient
mapping of mendelian traits in dogs through genome-wide association. Nat Genet. 2007; 39(11):1321–
8. https://doi.org/10.1038/ng.2007.10 PMID: 17906626.
22. Arendt ML, Melin M, Tonomura N, Koltookian M, Courtay-Cahen C, Flindall N, et al. Genome-Wide
Association Study of Golden Retrievers Identifies Germ-Line Risk Factors Predisposing to Mast Cell
Tumours. PLoS Genet. 2015; 11(11):e1005647. https://doi.org/10.1371/journal.pgen.1005647 PMID:
26588071; PubMed Central PMCID: PMCPMC4654484.
23. Hayward JJ, Castelhano MG, Oliveira KC, Corey E, Balkman C, Baxter TL, et al. Complex disease and
phenotype mapping in the domestic dog. Nat Commun. 2016; 7:10460. https://doi.org/10.1038/
ncomms10460 PMID: 26795439; PubMed Central PMCID: PMCPMC4735900.
24. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of
genetic variation. Nucleic Acids Res. 2001; 29(1):308–11. PMID: 11125122; PubMed Central PMCID:
PMCPMC29783.
25. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein func-
tion using the SIFT algorithm. Nat Protoc. 2009; 4(7):1073–81. https://doi.org/10.1038/nprot.2009.86
PMID: 19561590.
26. Rauscher R, Ignatova Z. Timing during translation matters: synonymous mutations in human patholo-
gies influence protein folding and function. Biochem Soc Trans. 2018. https://doi.org/10.1042/
BST20170422 PMID: 30065107.
27. Cannarozzi G, Schraudolph NN, Faty M, von Rohr P, Friberg MT, Roth AC, et al. A role for codon order
in translation dynamics. Cell. 2010; 141(2):355–67. https://doi.org/10.1016/j.cell.2010.02.036 PMID:
20403329.
28. Edwards NC, Hing ZA, Perry A, Blaisdell A, Kopelman DB, Fathke R, et al. Characterization of coding
synonymous and non-synonymous variants in ADAMTS13 using ex vivo and in silico approaches.
PLoS One. 2012; 7(6):e38864. https://doi.org/10.1371/journal.pone.0038864 PMID: 22768050;
PubMed Central PMCID: PMCPMC3387200.
29. Chamary JV, Hurst LD. Evidence for selection on synonymous mutations affecting stability of mRNA
secondary structure in mammals. Genome Biol. 2005; 6(9):R75. https://doi.org/10.1186/gb-2005-6-9-
r75 PMID: 16168082; PubMed Central PMCID: PMCPMC1242210.
30. Plotkin JB, Kudla G. Synonymous but not the same: the causes and consequences of codon bias. Nat
Rev Genet. 2011; 12(1):32–42. https://doi.org/10.1038/nrg2899 PMID: 21102527; PubMed Central
PMCID: PMCPMC3074964.
31. Wong GW, Zhuo L, Kimata K, Lam BK, Satoh N, Stevens RL. Ancient origin of mast cells. Biochem Bio-
phys Res Commun. 2014; 451(2):314–8. https://doi.org/10.1016/j.bbrc.2014.07.124 PMID: 25094046;
PubMed Central PMCID: PMCPMC4145527.
A synonymous variant associated with mast cell tumours in Labrador and Golden Retrievers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007967 March 22, 2019 30 / 33
32. Cooper DN. Functional intronic polymorphisms: Buried treasure awaiting discovery within our genes.
Hum Genomics. 2010; 4(5):284–8. https://doi.org/10.1186/1479-7364-4-5-284 PMID: 20650817;
PubMed Central PMCID: PMCPMC3500160.
33. Nelson KK, Green MR. Mechanism for cryptic splice site activation during pre-mRNA splicing. Proc Natl
Acad Sci U S A. 1990; 87(16):6253–7. PMID: 2143583; PubMed Central PMCID: PMCPMC54511.
34. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder:
an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009; 37(9):e67. https://doi.
org/10.1093/nar/gkp215 PMID: 19339519; PubMed Central PMCID: PMCPMC2685110.
35. Parker HG, Dreger DL, Rimbault M, Davis BW, Mullen AB, Carpintero-Ramirez G, et al. Genomic Anal-
yses Reveal the Influence of Geographic Origin, Migration, and Hybridization on Modern Dog Breed
Development. Cell Rep. 2017; 19(4):697–708. https://doi.org/10.1016/j.celrep.2017.03.079 PMID:
28445722; PubMed Central PMCID: PMCPMC5492993.
36. Donner J, Anderson H, Davison S, Hughes AM, Bouirmane J, Lindqvist J, et al. Frequency and distribu-
tion of 152 genetic disease variants in over 100,000 mixed breed and purebred dogs. PLoS Genet.
2018; 14(4):e1007361. https://doi.org/10.1371/journal.pgen.1007361 PMID: 29708978
37. Zeng R, Coates JR, Johnson GC, Hansen L, Awano T, Kolicheski A, et al. Breed distribution of SOD1
alleles previously associated with canine degenerative myelopathy. J Vet Intern Med. 2014; 28(2):515–
521. https://doi.org/10.1111/jvim.12317 PMID: 24524809
38. Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann
Oncol. 2011; 22 Suppl 1:i11–7. https://doi.org/10.1093/annonc/mdq660 PMID: 21285145.
39. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev
Genet. 2018; 19(9):581–590. https://doi.org/10.1038/s41576-018-0018-x PMID: 29789686
40. Bali V, Bebok Z. Decoding mechanisms by which silent codon changes influence protein biogenesis
and function. Int J Biochem Cell Biol. 2015; 64:58–74. https://doi.org/10.1016/j.biocel.2015.03.011
PMID: 25817479; PubMed Central PMCID: PMCPMC4461553.
41. Vedula P, Kurosaka S, Leu NA, Wolf YI, Shabalina SA, Wang J, et al. Diverse functions of homologous
actin isoforms are defined by their nucleotide, rather than their amino acid sequence. Elife. 2017; 6.
https://doi.org/10.7554/eLife.31661 PMID: 29244021; PubMed Central PMCID: PMCPMC5794254.
42. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human dis-
ease. Nat Rev Genet. 2011; 12(10):683–91. https://doi.org/10.1038/nrg3051 PMID: 21878961.
43. Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B. Synonymous mutations frequently act as driver
mutations in human cancers. Cell. 2014; 156(6):1324–35. https://doi.org/10.1016/j.cell.2014.01.051
PMID: 24630730.
44. Quax TE, Claassens NJ, Soll D, van der Oost J. Codon Bias as a Means to Fine-Tune Gene Expres-
sion. Mol Cell. 2015; 59(2):149–61. https://doi.org/10.1016/j.molcel.2015.05.035 PMID: 26186290;
PubMed Central PMCID: PMCPMC4794256.
45. Dana A, Tuller T. The effect of tRNA levels on decoding times of mRNA codons. Nucleic Acids Res.
2014; 42(14):9171–81. https://doi.org/10.1093/nar/gku646 PMID: 25056313; PubMed Central PMCID:
PMCPMC4132755.
46. Sagi D, Rak R, Gingold H, Adir I, Maayan G, Dahan O, et al. Tissue- and Time-Specific Expression of
Otherwise Identical tRNA Genes. PLoS Genet. 2016; 12(8):e1006264. https://doi.org/10.1371/journal.
pgen.1006264 PMID: 27560950; PubMed Central PMCID: PMCPMC4999229.
47. Dittmar KA, Goodenbour JM, Pan T. Tissue-specific differences in human transfer RNA expression.
PLoS Genet. 2006; 2(12):e221. https://doi.org/10.1371/journal.pgen.0020221 PMID: 17194224;
PubMed Central PMCID: PMCPMC1713254.
48. Kirchner S, Cai Z, Rauscher R, Kastelic N, Anding M, Czech A, et al. Alteration of protein function by a
silent polymorphism linked to tRNA abundance. PLoS Biol. 2017; 15(5):e2000779. https://doi.org/10.
1371/journal.pbio.2000779 PMID: 28510592; PubMed Central PMCID: PMCPMC5433685.
49. Gogakos T, Brown M, Garzia A, Meyer C, Hafner M, Tuschl T. Characterizing Expression and Process-
ing of Precursor and Mature Human tRNAs by Hydro-tRNAseq and PAR-CLIP. Cell Rep. 2017; 20
(6):1463–75. https://doi.org/10.1016/j.celrep.2017.07.029 PMID: 28793268; PubMed Central PMCID:
PMCPMC5564215.
50. Chan PP, Lowe TM. GtRNAdb 2.0: an expanded database of transfer RNA genes identified in complete
and draft genomes. Nucleic Acids Res. 2016; 44(D1):D184–9. https://doi.org/10.1093/nar/gkv1309
PMID: 26673694; PubMed Central PMCID: PMCPMC4702915.
51. Nakamura Y, Gojobori T, Ikemura T. Codon usage tabulated from international DNA sequence data-
bases: status for the year 2000. Nucleic Acids Res. 2000; 28(1):292. PMID: 10592250; PubMed Central
PMCID: PMCPMC102460.
A synonymous variant associated with mast cell tumours in Labrador and Golden Retrievers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007967 March 22, 2019 31 / 33
52. Nakamura M, Sugiura M. Translation efficiencies of synonymous codons for arginine differ dramatically
and are not correlated with codon usage in chloroplasts. Gene 2011; 472(1–2):50–54. https://doi.org/
10.1016/j.gene.2010.09.008 PMID: 20950677
53. Yamakawa K, Huot YK, Haendelt MA, Hubert R, Chen XN, Lyons GE, et al. DSCAM: a novel member
of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development
of the nervous system. Hum Mol Genet. 1998; 7(2):227–37. PMID: 9426258.
54. Schmucker D, Chen B. Dscam and DSCAM: complex genes in simple animals, complex animals yet
simple genes. Genes Dev. 2009; 23(2):147–56. https://doi.org/10.1101/gad.1752909 PMID: 19171779.
55. Peuss R, Wensing KU, Woestmann L, Eggert H, Milutinovic B, Sroka MG, et al. Down syndrome cell
adhesion molecule 1: testing for a role in insect immunity, behaviour and reproduction. R Soc Open Sci.
2016; 3(4):160138. https://doi.org/10.1098/rsos.160138 PMID: 27152227; PubMed Central PMCID:
PMCPMC4852650.
56. Jannot AS, Pelet A, Henrion-Caude A, Chaoui A, Masse-Morel M, Arnold S, et al. Chromosome 21
scan in Down syndrome reveals DSCAM as a predisposing locus in Hirschsprung disease. PLoS One.
2013; 8(5):e62519. https://doi.org/10.1371/journal.pone.0062519 PMID: 23671607; PubMed Central
PMCID: PMCPMC3646051.
57. Sharma S, Gao X, Londono D, Devroy SE, Mauldin KN, Frankel JT, et al. Genome-wide association
studies of adolescent idiopathic scoliosis suggest candidate susceptibility genes. Hum Mol Genet.
2011; 20(7):1456–66. https://doi.org/10.1093/hmg/ddq571 PMID: 21216876; PubMed Central PMCID:
PMCPMC3049353.
58. Schosser A, Butler AW, Uher R, Ng MY, Cohen-Woods S, Craddock N, et al. Genome-wide association
study of co-occurring anxiety in major depression. World J Biol Psychiatry. 2013; 14(8):611–21. https://
doi.org/10.3109/15622975.2013.782107 PMID: 24047446.
59. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, et al. Genome-wide association study on
overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
J Thorac Oncol. 2011; 6(1):132–8. https://doi.org/10.1097/JTO.0b013e318200f415 PMID: 21079520.
60. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of
Somatic Mutations In Cancer. Nucleic Acids Res. 2019; 47(D1):D941–D947. https://doi.org/10.1093/
nar/gky1015 Database [cited 2019 Jan 25] Available from: https://cancer.sanger.ac.uk/cosmic PMID:
30371878
61. Stockinger A, Eger A, Wolf J, Beug H, Foisner R. E-cadherin regulates cell growth by modulating prolif-
eration-dependent beta-catenin transcriptional activity. J Cell Biol. 2001; 154(6):1185–96. https://doi.
org/10.1083/jcb.200104036 PMID: 11564756; PubMed Central PMCID: PMCPMC2150811.
62. Mao X, Seidlitz E, Ghosh K, Murakami Y, Ghosh HP. The cytoplasmic domain is critical to the tumor
suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res. 2003; 63(22):7979–85. PMID:
14633730.
63. Vallath S, Sage EK, Kolluri KK, Lourenco SN, Teixeira VS, Chimalapati S, et al. CADM1 inhibits squa-
mous cell carcinoma progression by reducing STAT3 activity. Sci Rep. 2016; 6:24006. https://doi.org/
10.1038/srep24006 PMID: 27035095; PubMed Central PMCID: PMCPMC4817512.
64. Moh MC, Shen S. The roles of cell adhesion molecules in tumor suppression and cell migration: a new
paradox. Cell Adh Migr. 2009; 3(4):334–6. PMID: 19949308; PubMed Central PMCID:
PMCPMC2802741.
65. Taylor F, Murphy S, Hoather T, Dobson J, Scase T. TSLC1 tumour-suppressor gene expression in
canine mast cell tumours. Vet Comp Oncol. 2010; 8(4):263–72. https://doi.org/10.1111/j.1476-5829.
2010.00220.x PMID: 21062408.
66. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res. 2006; 34
(2):97–115. https://doi.org/10.1385/IR:34:2:97 PMID: 16760571; PubMed Central PMCID:
PMCPMC1490026.
67. Amin K. The role of mast cells in allergic inflammation. Respir Med. 2012; 106(1):9–14. https://doi.org/
10.1016/j.rmed.2011.09.007 PMID: 22112783.
68. Cao W, Hashibe M, Rao JY, Morgenstern H, Zhang ZF. Comparison of methods for DNA extraction
from paraffin-embedded tissues and buccal cells. Cancer Detect Prev. 2003; 27(5):397–404. PMID:
14585327.
69. Lequarre AS, Andersson L, Andre C, Fredholm M, Hitte C, Leeb T, et al. LUPA: a European initiative
taking advantage of the canine genome architecture for unravelling complex disorders in both human
and dogs. Vet J. 2011; 189(2):155–9. https://doi.org/10.1016/j.tvjl.2011.06.013 PMID: 21752675.
70. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559–75.
https://doi.org/10.1086/519795 PMID: 17701901; PubMed Central PMCID: PMCPMC1950838.
A synonymous variant associated with mast cell tumours in Labrador and Golden Retrievers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007967 March 22, 2019 32 / 33
71. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies. Nat Genet.
2012; 44(7):821–4. https://doi.org/10.1038/ng.2310 PMID: 22706312; PubMed Central PMCID:
PMCPMC3386377.
72. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From
FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr
Protoc Bioinformatics. 2013; 43:11 0 1–33. https://doi.org/10.1002/0471250953.bi1110s43 PMID:
25431634; PubMed Central PMCID: PMCPMC4243306.
73. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of geno-
mic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010; 26(16):2069–70.
https://doi.org/10.1093/bioinformatics/btq330 PMID: 20562413; PubMed Central PMCID:
PMCPMC2916720.
74. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps.
Bioinformatics. 2005; 21(2):263–5. https://doi.org/10.1093/bioinformatics/bth457 PMID: 15297300.
75. de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic
association studies. Nat Genet. 2005; 37(11):1217–23. https://doi.org/10.1038/ng1669 PMID:
16244653.
76. Nolan T, Hands RE, Ogunkolade W, Bustin SA. SPUD: a quantitative PCR assay for the detection of
inhibitors in nucleic acid preparations. Anal Biochem. 2006; 351(2):308–10. https://doi.org/10.1016/j.
ab.2006.01.051 PMID: 16524557.
77. Das M, Chu LL, Ghahremani M, Abrams-Ogg T, Roy MS, Housman D, et al. Characterization of an
abundant short interspersed nuclear element (SINE) present in Canis familiaris. Mamm Genome. 1998;
9(1):64–9. PMID: 9434948.
78. Marullo M, Zuccato C, Mariotti C, Lahiri N, Tabrizi SJ, Di Donato S, et al. Expressed Alu repeats as a
novel, reliable tool for normalization of real-time quantitative RT-PCR data. Genome Biol. 2010; 11(1):
R9. https://doi.org/10.1186/gb-2010-11-1-r9 PMID: 20109193; PubMed Central PMCID:
PMCPMC2847721.
79. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification
framework and software for management and automated analysis of real-time quantitative PCR data.
Genome Biol. 2007; 8(2):R19. https://doi.org/10.1186/gb-2007-8-2-r19 PMID: 17291332; PubMed Cen-
tral PMCID: PMCPMC1852402.
A synonymous variant associated with mast cell tumours in Labrador and Golden Retrievers
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007967 March 22, 2019 33 / 33
